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THE HYPOXIC ADENOSINE RESPONSE MODULATES MACROPHAGE
DIFFERENTIATION AND CONTRIBUTES TO LUNG DISEASE
Kemly Mary Philip, M.B.E., B.S.B.E.
Supervisory Professor: Michael R. Blackburn, Ph.D.

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease which affects 5 8 million individuals worldwide and 200,000 individuals in the United States alone.
Although prevalent, we do not know what causes IPF and no effective curative
treatment exists for this disease. Our laboratory has shown that extracellular
accumulation of adenosine and subsequent activation of the adenosine 2B
(ADORA2B) receptor promotes immune cell invasion, airspace destruction, and
fibrosis in chronic lung disease. Additionally, alternatively activated alveolar
macrophages (AAMs) expressing ADORA2B, have been implicated in mediating
adenosine’s pro-fibrotic effects in IPF. However, the exact role of AAMs in the hypoxic
lungs of IPF patients is not known. Our results reveal myeloid-specific ADORA2B
deletion, antagonism of ADORA2B on AAMs, and inhibition or genetic silencing of
hypoxia inducible factor 1 (HIF1A) as a means to attenuate pro-fibrotic mediator
production and pulmonary fibrosis in bone marrow derived macrophages (BMDMs)
and in vivo models of bleomycin-induced pulmonary fibrosis. These players will be
valuable as potential clinical targets to halt differentiation of macrophages into the
reparative AAM subtype and attenuate their subsequent pro-fibrotic role. Ultimately,
these investigations will lead to a better understanding of adenosine’s role in IPF and
lead to identification of targets for novel therapeutics that can prevent disease
progression and possibly reverse lung fibrosis.
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CHAPTER ONE
INTRODUCTION
IDIOPATHIC PULMONARY FIBROSIS
Definition and Epidemiology
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown
cause which leads to chronic, progressive interstitial pulmonary fibrosis(1). It is a
disease which typically affects older males between the ages of 55 and 75(2). IPF is
believed to affect up to 200,000 alone in the United States and around 8 million
individuals worldwide (2-4). Nalysnyk et al. estimate the prevalence in the United
States to be between 42.7-63 cases per 100,000 based on broad case definitions of
IPF(5). Approximately 14,000 – 34,000 patients receive the new diagnosis of IPF each
year(3). Ultimately, prevalence and incidence of IPF has been shown to increase with
age and is continuing to rise emphasizing the need for investigation into the
pathogenesis of this disease and development of novel therapies to halt its increasing
incidence (1, 5).

Presentation and Diagnosis
Patients with IPF typically present with a chronic, non-productive cough and
progressive dyspnea, or shortness of breath, on exertion which severely limits their
quality of life(1, 2, 6). Findings on physical examination will include digital clubbing or
bibasilar inspiratory crackles(2). Diagnosing IPF requires excluding other known
causes of interstitial lung disease, the presence of a usual interstitial pneumonia (UIP)
on high resolution computed tomography (HRCT) in patients without surgical lung
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biopsy, or findings of possible UIP on HRCT with surgical lung biopsy findings showing
definite UIP, probable/possible UIP, or non-classifiable fibrosis in conjunction with
multidisciplinary discussion(1). Findings of definite UIP on histopathology include
marked fibrosis, including patchy parenchymal involvement, fibroblastic foci, and
honeycombing in a subpleural or septal distribution in the absence of any features
suggestive of a different diagnosis (1). Honeycombing refers to clustered cystic
airspaces with thick, fibrous walls and findings of collapsed alveoli and dilated alveolar
lumen on pathology (7). HRCT findings suggestive of definite UIP include subpleural
or basal predominance of reticular abnormalities, honeycombing with or without
traction bronchiectasis, provided there is no evidence of features inconsistent with UIP
such as micronodules, cysts, or consolidation(1).

Risk Factors
Although there is no known cause for IPF, risk factors such as environmental
exposures, genetic factors, or medical comorbidities may contribute to the
development of disease(2). A smoking history greater than 20 pack-years has strong
associations with familial and sporadic IPF(1). Environmental exposures to metal,
wood, vegetable, or animal dust is associated with significantly increased risk of IPF
putting those who work in farming, hair dressing, or livestock at risk(1).
Co-morbid conditions including obesity, obstructive sleep apnea (OSA),
diabetes, and gastro-esophageal reflux disease (GERD) have been associated with
IPF(2). 37-94% of patients with IPF are affected by GERD(8). It’s postulated that
fibrosis changes compliance of the lung, contributing to increased negative
18

intrathoracic pressure and the symptoms of acid reflux; another hypothesis that
repeated microaspirations contribute to alveolar epithelial cell damage which
contributes to the repair, remodeling, and abnormal extracellular matrix deposition
which leads to IPF (1, 8). Diabetes mellitus is found in 10-32.7% of patients with IPF(9)
however the mechanism by which it may contribute to the pathogenesis of IPF is
unclear. Some studies have suggested an association with Epstein-Barr virus (EBV)
and hepatitis C infection in association with IPF however these studies are limited due
to negative associations in some and significant confounding variables including
immunosuppressive treatment(1).
Genetic transmission between families is believed to only affect up to 3.7% of
patients with IPF (2). ELMOD2, a gene found on chromosome 4q31, in addition to
mutations in surfactant protein C (spc) and the rare surfactant protein A2 (SFTPA2)
have been found to be strongly associated with familial cases of IPF, where two or
more members of the primary biological generation are affected (1). Mutations in
human telomerase reverse transcriptase (hTERT) and human telomerase RNA (hTR)
have been found in 15% of familial IPF cases supporting the hypothesis that
progressive telomere shortening contributes to alveolar epithelial cell apoptosis and
the initiation of an abnormal wound repair response which leads to the development
of IPF(1, 2). Sporadic cases of IPF have been associated with genetic polymorphisms
in genes coding for cytokines (interleukin-1, 4, 8, 10, and 12, and tumor necrosis
factor alpha (TNF), enzymes (1-antitrypsin, angiotensin converting enzyme), profibrotic mediators including transforming growth factor 1 (TGF1), and matrix
metalloproteinase (MMP)-1(1, 10). Recent work by Yang et al. suggest genetic
polymorphisms in the promoter of mucin 5B (MUC5B) has a strong association with
19

the development of IPF and its increased expression in terminal bronchi suggest
increased mucous production contributes to perturbed mucociliary clearance and the
development of pulmonary fibrosis(11).

Natural History of IPF
A large majority of patients with IPF follow a slow, gradual progression of
disease while some remain stable, show a rapid decline, or demonstrate repeated
acute exacerbations (AE)(1). Risk factors that may influence the disease progression
are not quite understood but emphysema and pulmonary hypertension are believed
to have a role(1). Patients with a stable or slowly progressive course of disease
typically do not present to physicians until years (typically >24 months) after the
symptoms begin although mortality is typically within few years of diagnosis (2, 12).
Their annual decline in forced vital capacity typically ranges from 0.13 to 0.21L(12).
Patients are diagnosed with the rapidly progressive IPF subtype when they
present to their physician within six months of symptoms beginning(12). Although their
pulmonary function and findings on histology or imaging at the time of diagnosis are
similar to patients with the slowly progressive subtype, patients with accelerated IPF
are typically male, smokers, and have been found to have greatly differing
transcriptional profiles(2). Smoking has been shown to induce inflammation and
contribute to upregulation of the MAPK-ERG1-HSP70 pathway(13). Microarray data
from patients with rapidly versus slowly progressive IPF found 437 differentially
expressed genes including overexpression of genes related to morphogenesis,
oxidative stress, migration and proliferation of fibroblasts and smooth muscle
20

cells(14). Immunohistochemistry of lung sections from rapid progressors also showed
increased staining of ADORA2B in alveolar epithelial cells(14).
Five to ten percent of patients will experience repeated acute exacerbations
(AE) or periods of respiratory decline within days to weeks(1). Acute exacerbations
may be secondary to infection or cardiac failure(1). If in the absence of a known cause
but associated with worsening symptoms of one month, lung function, bilateral
ground-glass opacities and reticular consolidation on HRCT, is then referred to as
acute exacerbations of IPF(1, 12). Mortality amongst these patients exceeds 60%
during hospital admissions and increases to 90% within 6 months after discharge(2).
Although there are no established risk factors for AE of IPF, it has been associated
with post-operative thoracic surgery, bronchoalveolar lavage fluid (BAL) collection,
and Torque teno virus in 27% of affected patients(2, 12). It is unclear however if AE
of IPF represent a separate disease process from IPF or results from acute pulmonary
distress leading to exacerbations of fibrotic changes in IPF(15). Examination of BAL
typically reveals neutrophilia and histology shows diffuse alveolar damage (DAD)
indicative of alveolar epithelial cell injury and remodeling as a mechanism of injury in
AEs of IPF(15).

Treatment
In the past, as IPF was believed to largely be a disease secondary to
aggressive inflammation alone, treatment had been primarily limited to corticosteroid
treatment with no significant clinical improvement, little survival benefits and significant
long-term comorbidities(1, 15).
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Pharmacologic therapies which have failed placebo-controlled trials include
Etanercept, a recombinant soluble human TNF receptor which binds and neutralizes
TNF, an inflammatory cytokine found to be elevated in patients with IPF(15).
Bosentan, an endothelin-1 (ET-1) receptor antagonist, was predicted to inhibit ET-1mediated collagen production, and matrix turnover; however, the BUILD-1 study
showed no significant difference over placebo in 6 minute walking distance (6MWD)
among treated patients(15). Similarly, macitentan, a nonselective ET receptor
antagonist, was shown to have little effect on forced vital capacity against placebo in
a phase 2 trial(16).

The phase 3, randomized, double-blind, placebo-controlled

anticoagulant effectiveness in idiopathic pulmonary fibrosis (ACE-IPF) trial was
suspended due to ineffectiveness of warfarin treatment in patients with IPF over
placebo(2).
Sildenafil, a phosphodiesterase 5 inhibitor, decreases pulmonary vascular
constriction, reduces resistance, and has been shown to improve gas exchange and
dyspnea in patients with severe IPF although no differences in 6MWD, the primary
outcome was observed (2, 17).
The PANTHER-IPF study evaluated the change in baseline FVC after 60
weeks among patients with mild to moderate IPF who received either treatment with
placebo, N-acetylcysteine (NAC) monotherapy, or prednisone and azathioprine and
NAC therapy(18). No significant difference was observed in the rate of FVC decline or
frequency of AEs(18). There were frequent hospital admissions and eight deaths in
the three-drug group which prompted the Data and Safety Monitoring Board to stop
the study and discontinue the use of the triple-drug therapy(18).
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Pirfenidone is believed to inhibit fibroblast proliferation and collagen production
through its inhibition of TGF and TNFInitial Phase II trials showed no difference in
pirfenidone treatment as compared to placebo with respect to changes in arterial
oxygen saturation after 6MWD however vital capacity (VC) was significantly
improved(19). A phase III randomized control trial in Japan revealed significant
differences in VC decline between placebo and high or low dose treatment groups
leading to its approval in 2008 for the treatment of IPF(20). The multinational phase II
CAPACITY 1 trial showed significant difference in % FVC change from baseline after
72 weeks in patients with pirfenidone treatment as compared to placebo leading to its
approval in European countries in 2011 for IPF treatment(21). It was not until the
phase III ASCEND trial which demonstrated improvements in FVC, 6MWD,
progression free survival, and a reduction in death at 1 year by 48% that the FDA
approved pirfenidone for treatment of IPF patients in the United States in October
2014(22). Mild to moderate side effects include gastrointestinal, dermatologic,
neurological symptoms, and elevated liver enzymes(23).
Nintedanib inhibits vascular endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF), and fibroblast growth factor (FGF) receptors halting the
progression of fibrosis, slowing the decline in FVC, and AEs in patients receiving
treatment compared to placebo. Phase III trials showed twice daily administration of
nintedanib for 52 weeks led to slowing of the rate of FVC decline although there was
no difference with respect to time to AE. Given these results however, Nintedanib was
approved by the FDA for treatment of patients with IPF in October 2014 as well(24).
Diarrhea was a significant adverse effect which impacted 90% of patients(23).
However, a recent network meta-analysis comparing Pirfenidone and Nintedanib
23

show no significant difference in either drug’s ability to lower respiratory-specific or allcause mortality or decline in percent FVC (22, 24, 25).
Lung transplant remains the only ‘curative’ treatment that can increase survival,
and even then, it only mildly improves 5 year survival rates to 50-56%(1). Other
supportive and preventative treatment approaches include pulmonary rehabilitation,
smoking cessation, immunization against influenza and pneumococcus, control of
GERD, and oxygen therapy to keep saturations above 90%(15). There is some recent
evidence however which suggests that oxygen therapy may not have any additional
benefit over air in reducing exertional dyspnea among IPF patients without hypoxemia
at rest(6).
Recent compounds in Phase 2 clinical trials include Fresolimumab, which targets
TGF, FG-3019, a monoclonal antibody against connective tissue growth factor,
Rituximab which targets Anti-CD20, and Sirolimus which inhibits mTOR(23). Several
compounds have been developed against IL-13 including Lebrikizumab, OAX-576,
Tralokinumab, and SAR156597 which actually targets IL-13 and IL-4(23).

Prognosis
Median survival for patients with IPF is between 2-3 years secondary to
ineffective therapies (2, 26). There were approximately 175, 000 deaths due to
pulmonary fibrosis from 1992 to 2003 which is about 51 deaths per 1,000,000 people
when adjusted by age and sex. In fact, mortality during that time period increased by
28.4% in men and 41.3% in women(27). Five year survival rate among patients with
IPF is only 43%(28). Poor prognostic factors include age greater than 70 years old,
smoking history greater than 20 pack-year, and low body mass index (2). Other factors
24

of poor prognosis at baseline include diffusion limited capacity less than 40% of
predicted, desaturations in arterial oxygen saturation to less than 88% during 6MWT,
reductions in FVC by more than 10%, extensive honeycombing on HRCT, and
pulmonary hypertension(1, 23). 9.8-38% of IPF patients may go on to develop
malignancies including bronchogenic carcinoma(2).

Pathogenesis of IPF
Despite its significant prevalence, little is known about the mechanisms that
lead to the development and progression of IPF and contributes to its poor prognosis
(15). The failure of anti-inflammatory therapies for IPF including corticosteroids has
largely refuted the hypothesis that IPF is primarily an inflammatory condition (2, 15).
Epithelial cell injury and activation by genetic and environmental factors discussed
above including smoke exposure, chronic microaspirations, or infection are instead
believed to be the main pathway contributing to the development of fibrosis(15).
Alveolar epithelial cells have been shown to secrete mediators which promote
recruitment, proliferation, and differentiation of mesenchymal cells, fibrocyte
infiltration; in fact, transitions of epithelial cells to mesenchymal cells (termed EMT or
epithelial to mesenchymal transition) is believed to account for 33% of fibroblasts in
mouse models of lung fibrosis(2). Hung et al. have also demonstrated the presence
of pericytes, or cells derived from Foxd1-expressing progenitors, which expand after
bleomycin-induced injury to myofibroblasts and fibroblasts and contribute to the
deposition of extracellular matrix and fibrosis(29).
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Proteins critical to embryogenesis have also been found to be abnormal in IPF.
Wnt ligands have found to be overexpressed in alveolar epithelium and fibroblasts
from IPF patients in addition to downregulation of phosphatase and tensin homologue
(PTEN) in myofibroblasts, contributing to their resistance to apoptosis(2).
Myofibroblasts are essentially ‘activated’ fibroblasts with greater contractility and profibrotic potential(2). Increased gremlin expression, a bone morphogenetic protein
antagonist, has also been observed in IPF fibroblasts (2). Moreover, much remains
to be understood regarding the pathogenesis of lung tissue injury, remodeling, and
fibrosis development emphasizing the significance of work presented in this
dissertation.

ACUTE LUNG INJURY
Definition and Epidemiology
Acute lung injury (ALI) is a devastating lung disease of acute onset which often
progresses into acute respiratory distress syndrome (ARDS), respiratory failure, and
death(30). It is characterized by pulmonary edema due to breakdown and increased
permeability of the alveolar capillary barrier which contributes to impaired arterial
oxygen saturation in affected patients (31). It is estimated that the incidence in the
United States is 190,600 individuals per year(30, 32). Although incidence of hospitalacquired ARDS is declining since changes in standard of practice with respect to lungprotective mechanical ventilation, the incidence of community-acquired ARDS
remains the same(32). Moreover, there still remains a large clinical need to identify
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mechanisms behind the development of inflammation, pulmonary edema, and
hypoxemia in order to develop targeted therapeutics that can reduce its incidence.

Presentation and Diagnosis
Patient typically present with tachypnea, or increased respiratory rate, and
hypoxemia(30). Criteria for diagnosis of ALI include acute onset within 1 week of a
known insult or worsening symptoms, the presence of diffuse pulmonary infiltrates,
PaO2/FiO2 ≤ 300, and the absence of symptoms that suggest cardiac failure (31, 32).
Early phases of disease show bilateral, ground-glass opacities which develop
secondary to interstitial edema and hyaline membrane deposition(30).
Epithelial and endothelial barrier dysfunction contribute to diffuse alveolar
damage (DAD) which can be classified into three phases on histology. In the acute or
exudative phase, hyaline membranes are observed lining the alveolar space in
addition to edema with contributing to the eventual development of granulation tissue;
alveolar hemorrhage may be present and type II epithelial cells become
hyperplastic(30). In the proliferative phase, granulation tissue incorporates into the
alveolar septa leading to squamous metaplasia(30). Finally, the fibrotic phase is
characterized by collagen deposition and alveolar hyalinization(30).

Risk Factors
Generally, risk factors for ALI can be divided into predisposing medical
conditions, including shock, sepsis, aspiration, pneumonia, and surgery, or risk
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modifiers

such

as

obesity,

alcohol

abuse,

tachypnea,

and

oxygen

supplementation(32). However, infection including pneumonia or sepsis are the
greatest factors shown to lead to ALI development at 46% and 33%, respectively(32).
Additionally triggers which directly affect the lung including microaspiration,
ingestants, inhalants, hyperoxia, ventilator induced injury, and bleomycin can lead to
the development of ALI (30, 31). Systemic inflammatory response syndrome (SIRS)
in response to pancreatitis or transfusions can also contribute to ALI(31). Patients with
other medical comorbidities including chronic lung disease or alcohol abuse are also
found to have increased incidence of ALI(32). Interestingly, both Type 1 and Type 2
diabetes mellitus has been found to have a protective effect in septic and nonseptic
patients with ALI(32).

Treatment
Treatment is primarily aimed at addressing the underlying cause in addition to
supportive care which may include mechanical ventilation and corticosteroid therapy.
Phase 3 trials demonstrated significant reductions in mortality and greater ventilatorfree days when low tidal volumes are used (6cc/kg of predicted body weight)(33).
Implementation of changes in mechanical ventilation based on these trials has
contributed to the reduced incidence by almost 40% of ALI developing into hospitalacquired ARDS(32).
The Lung Injury Prevention study with Aspirin (LIPS-A) is a recent phase 2 trial
which evaluated the impact of prophylactic aspirin administration versus placebo on
reducing ALI incidence in patients already on invasive mechanical ventilation;
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however no reductions in ARDS incidence was observed so a phase 3 trial was not
initiated(34). The recent phase 2 clinical trial evaluating aerosolized budesonide, an
inhaled corticosteroid, and formoterol, a beta-agonist, treatment against placebo
shows promise however in that combined treatment demonstrated improvements in
oxygenation, PaO2/FiO2 ratio, decreased incidence of ARDS, and reductions in
hospital stay(35).

Prognosis
Typically, patients with ALI will develop ARDS within 2-5 days of
hospitalization(30). Factors which influence mortality include ALI severity whether it
be mild (200 < PaO2/FiO2 ≤ 300), moderate (100 < PaO2/FiO2 ≤ 200), or severe
(PaO2/FiO2 ≤ 100) associated with increasing mortality rates of 27%, 32%, or 45%
respectively(32). Males and African Americans affected by ALI also exhibit increased
mortality however rates generally declines as time from admission increases(30, 32).
Since 2010, the rate of in-hospital mortality is approximately 45%, ICU-associated,
38%, 30d after discharge, 30%, and 32% at 60 days from discharge(36). Overall
however, there has been no significant improvement in mortality over the past two
decades (30, 31).

Pathogenesis of ALI
There is extensive evidence suggesting the role of inflammation in ALI. After
the initial insult, neutrophils are often the first cell type to infiltrate the lung releasing
chemokines that attract macrophages and other mononuclear cells(37). Activated
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neutrophils release proteases, reactive oxygen species (ROS), and peptides that
contribute to the apoptotic and necrotic cell death of endothelium and epithelium(37).
This breakdown of the pulmonary barrier contributes to increased permeability,
pulmonary edema, and further inflammation (37, 38). Therapeutic inhibition of
neutrophil-dependent CXCR2 (the chemokine receptor for IL-8, a known neutrophil
chemoattractant) in a bleomycin-induced model of ALI was shown to be protective in
addition to bleomycin exposure in IL-1-/- and IL-18-/- mice(31). These studies highlight
the importance of neutrophil migration and activation in contributing to acute lung
injury. Recruited anti-inflammatory macrophages also play a key role in resolving
inflammation. Janssen et al demonstrated the importance of Fas-mediated apoptosis
in bone-marrow recruited macrophages (CD11bhigh) in resolving inflammation in a
H1N1-model of acute lung injury while populations of resident macrophages
(CD11chigh) were stable (39).
Chemokines including macrophage inflammatory protein-1alpha (MIP-1), a
monocyte and leukocyte chemoattractant contributes to acute inflammation in acute
lung injury models through TNF and IL-6 release (38). Monocyte chemotactic
protein-1 (MCP-1) is a chemokine produced by mononuclear cells including lung
macrophages and contributes to increased inflammation in the development of lung
injury(38). BALF levels of chemokines including CXCL1 and CXCL8 are elevated in
patients with ALI(40). As such, some investigators have focused on antibody blockade
of chemokines and or their receptors to attenuate ALI in animal models of disease
however these findings have yet to be translated to trials in humans with ALI/ARDS.
Pathogen associated molecular patterns (PAMPs) and damage-associated
molecular patterns (DAMPs) typically serve to initiate responses by the innate immune
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system including TNF, IL1, and IL-8 release(30). One key DAMP includes
hyaluronan, an extracellular matrix glycosaminoglycan, produced in the setting of lung
injury binds Toll-like receptors (TLR) 4 and 2 inducing inflammation(30). In fact,
overexpression of high-molecular weight hyaluronan has been shown to be protective
against lung injury in animal models by NF-kappaB activation protecting from further
epithelial cell apoptosis(41).
Biomarkers to date which have been found to be elevated in plasma and BAL
amongst patients with ALI include TNF, IL-1, IL-6, IL-8, and IL-18(30). IL-8 is
interesting of note due to its ability to activate and attract neutrophils by binding with
anti-IL-8 autoantibodies which inhibit neutrophil apoptosis(42, 43). Neutrophils are
one of the first cells to respond and infiltrate the lung after ALI(31). Additionally,
concentration of these IL-8-anti-IL-8 autoantibodies along with IL-18 levels is a direct
indicator of ALI disease severity and mortality (44, 45). Despite the advances in
understanding the pathophysiology which lead to the development of acute lung injury,
there are few molecular-based therapies which have been shown to reduce mortality
and improve quality of life for the patients who survive ALI and ARDS; as such,
findings presented in this thesis on the impact of hypoxia and HIF1A stabilization are
valuable to driving development of novel treatments for ALI.

ADENOSINE SIGNALING IN LUNG DISEASE
Adenosine Metabolism and Signaling
Adenosine is a potent signaling molecule that exerts its effects by acting on
four G-protein coupled receptors (GPCRs), ADORA1, ADORA2A, ADORA2B, AND
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ADORA3(46, 47). These receptors lead to changes in intracellular cAMP and calcium
which ultimately, regulate homeostatic functions within the cell(48). ADORA1 and
ADORA3 are Gi coupled so activation leads to reduced cAMP levels while ADORA2A
and ADORA2B are Gs coupled stimulating adenyl cyclase, increasing cAMP and
protein kinase A activation(48). ADORA2B can also couple to Gq stimulating
phospholipase C (PLC) contributing to calcium release and protein kinase C (PKC)
activation(48). Generally, the ADORA1 and ADORA2A receptor have higher affinity
for adenosine than the low-adenosine affinity ADORA2B and ADORA3A
receptors(49). Physiologic levels of adenosine in the extracellular fluid range from 40600nM and its accumulation in the extracellular space is secondary to passive transfer
from the intracellular space (50). Two bi-directional carriers responsible for passive
diffusion of adenosine are equilibrative nucleoside transporter (ENT)-1 and ENT2(49). Adenosine can be deaminated to inosine by adenosine deaminase (ADA) or
phosphorylated by adenosine kinase to ATP(49).
In settings of cellular injury induced by hypoxia, trauma, or chronic
inflammation, ATP is released from affected cells and subsequently dephosphorylated
by the membrane bound enzyme ectonucleoside triphosphate diphosphohydrolase
CD39 to AMP followed by dephosphorylation to adenosine by ecto-5’-nucleotidase
CD73 to produce elevations in adenosine in the extracellular space(51, 52).
Adenosine concentrations have been found to be as elevated as 100M in asthma
and COPD(50). Activation of the different adenosine receptors have been found to
have differing effects depending on the injury model and cell-type. For example,
antagonism of ADORA1 and ADORA3 have been associated with reduced
inflammation in models of cecal ligation (50). ADORA2A has been shown to maintain
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integrity in cardiac and renal models of ischemic reperfusion injury while ADORA2A
provides systemic organ protection (50).

Adenosine Signaling in Chronic Lung Disease
Previous work suggests that pulmonary fibrosis results from an abnormal tissue
reparative response(53). We have demonstrated how the nucleoside adenosine plays
a critical role in the regulation of this response in the lung and contributes to
fibrosis(50, 54-56). Adenosine levels are elevated in chronic lung diseases including
asthma, COPD, and IPF(55, 57, 58). Mouse models of lung injury show increased
adenosine levels in bronchoalveolar lavage fluid associated with increased
inflammation and fibrosis(56).
These elevations in adenosine have been found to have differing tissue protective
versus tissue destructive effects depending on the adenosine receptor activated and
cell type. One mouse model that has been used to understand the effects of
adenosine-mediated lung injury is the Adenosine Deaminase (ADA) deficient model
(ADA-/-) in which adenosine accumulates in the extracellular space due to the lack of
the ADA enzyme which catalyzes its breakdown(59). ADA-/- mice exhibit abnormalities
in alveologenesis, airway enlargement and obstruction, along with pulmonary
inflammation, that contributes to the development of pulmonary fibrosis which is
attenuated with introduction of ADA enzyme supplementation (60, 61). This model has
ultimately allowed evaluation of adenosine-mediated lung injury. Adenosine
stimulation itself promotes release of IL-8, IL-4, and IL-13 from mast cells. Overall,
ADORA1 and ADORA2A have been found to have a tissue-protective role in
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adenosine-mediated lung injury as ADA-/-/ADORA1-/- and ADA-/-/ADORA2A-/- mice
showed exacerbations in inflammation and mucous cell metaplasia(62, 63).
Meanwhile, activation of ADORA2B and ADORA3 are associated with tissuedestructive effects enhancing inflammation and fibrosis, or mast cell degranulation
and mucous metaplasia, respectively (50).
The ADORA2B receptor is unique in several ways including its low affinity for
adenosine and promotion of anti-inflammatory and anti-fibrotic features in acute lung
injury(54). However, our lab has previously shown that chronic extracellular adenosine
accumulation and activation of ADORA2B receptor can lead to features of chronic
lung disease including inflammation, fibrosis, and tissue remodeling (56). Evaluating
lung sections from IPF patients who are rapid progressors has also shown increased
immunohistochemical staining for ADORA2B in association with increases in matrix
metalloproteinases (MMPs) in IPF BALF promoting increased fibroblast migration in
comparison with slow progressors (14).
ADORA2B is found throughout many cell types in the lung including epithelial
cells, macrophages, fibroblasts, and smooth muscle cells (64). However, ADORA2Bmediated release of the pro-inflammatory and pro-fibrotic cytokine, IL-6, from
macrophages has proven to be of unique interest. IL-6 itself is known to target
inflammatory mediators including CXCL1, MCP-1, osteopontin (OPN), and IL-17 (65).
CXCL1 itself, the murine analog of human neutrophil chemoattractant, IL-8, was found
to be elevated in lungs of ADA-/- mice and neutralization of CXCL1 and its receptor,
CXCR2, was found to inhibit adenosine-mediated angiogenic activity in the lung(66).
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Zhou et al. demonstrated ADORA2B expression on CD206 positive macrophages
in macrophages from BALF of IPF patients and revealed a role for ADORA2B
antagonism in decreasing IL-6 production from macrophages isolated from IPF
patients (55). Supporting a role for ADORA2B in mediating IL-6 production,
ADORA2B-/- mice were observed to have reduced IL-6 expression in BALF on day 33
after bleomycin exposure in association with reductions in IL-6 immunohistochemical
staining localized to lung macrophages(56). Lung macrophages isolated from ADA-/mice, known to have exacerbated inflammation, alveolar destruction and fibrosis
secondary to adenosine elevations, showed elevations in IL-6 transcripts which were
further increased with treatment by the adenosine receptor agonist, NECA, and
reversed upon addition of ADORA2B-specific antagonist, MRS 1754 (65).

Adenosine Signaling in Acute Lung Injury
As discussed above, ALI is characterized by initial influx of neutrophils into the
lungs and a Th1 cytokine rich environment including increases in IL-12, IFN, and
TNF(50). Models of LPS-induced ALI have demonstrated exacerbations neutrophilia
and pulmonary barrier dysfunction in CD39 and CD73 deficient mice associated with
reductions in adenosine thereby suggesting adenosine itself plays an antiinflammatory role in ALI(67). ADORA2A and ADORA3 agonists have also been
utilized in transplantation lung reperfusion injury models and cardiopulmonary bypassinduced lung injury models to attenuate inflammation and preserve pulmonary
function(50). ADORA2B antagonist treatment in a ventilator-induced lung injury model
demonstrated increases in pulmonary inflammation, edema, decreased gas
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exchange, and reductions in survival time (68). Similarly, we have previously
demonstrated a tissue-protective role for ADORA2B as exacerbations in pulmonary
edema, inflammation, and barrier dysfunction were observed in ADORA2B -/- mice
exposed to bleomycin intratracheally(56). Bleomycin treatment of ADORA3-/- mice
also showed enhanced inflammation and eosinophilia suggesting ADORA3 also
serves an anti-inflammatory role in ALI (69).
Evidence in animal models of acute and chronic lung disease and patient
samples reveal that adenosine receptors have differing anti-inflammatory, tissueprotective or pro-inflammatory, tissue-destructive roles depending on the stage of
disease or cell-type involved(50, 52). Although it is not clearly understood what
contributes to these differences depending on disease stage, it may likely be a feature
of differences in the cytokine environment with acute injury being primarily Th1 and
chronic stages of disease, Th2 (50). This dissertation will focus on the role of
ADORA2B on myeloid cells in acute lung injury and chronic lung disease in a
bleomycin-induced model of lung injury along with how hypoxia can regulate these
responses.

HYPOXIA-INDUCIBLE FACTOR 1A (HIF1A) IN LUNG DISEASE
Hypoxia inducible factor-1A (HIF1A) Signaling
Hypoxia inducible factor (HIF) is a transcription factor responsible for regulating a
variety of target genes including those involved in angiogenesis, matrix metabolism,
apoptosis, and glycolysis(70, 71). It is composed of two subunits: the inducible alpha
(HIF1A) and constitutively expressed beta unit (HIF1B)(70). In normoxic conditions,
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von hippel Lindau (VHL) protein targets the HIF1A subunit for proteasomal-mediated
degradation followed by prolyl hydroxylation of the oxygen dependent domain (ODD)
by three prolyl hydroxylases (PHD 1,2 and 3)(70). Another player which can disrupt
HIF transcription is Factor inhibiting HIF1, or FIH. FIH hydroxylates asparagine
residues within HIF1A or HIF2A, preventing the interaction of HIF with its
transcriptional co-activator p300.(70).
In settings of hypoxia, PHD enzyme activity decreases resulting in decreased
hydroxylation of HIF1A promoting its stabilization and accumulation in the
cytoplasm(72). Next, it translocates to the nucleus where it binds to the constitutively
expressed HIF1B and the heterodimer bind to hypoxia response elements (HRE) on
the promoter region of target genes, recruits coactivator proteins, and initiates
transcription of the target gene (71).
HIF1A can also be stabilized in normoxic conditions such as bacterial
lipopolysaccharide (LPS) treatment, iron uptake by bacteria during infection, or
mechanical stretch which increases ROS inhibiting PHDs(73, 74). NF-kb activation of
the innate immune system, PI3K/Akt pathway activation in response to insulin-like
growth factor (I-LGF) can also stabilize HIF1A in the absence of hypoxia(74, 75).
Elevations in succinate have also been shown to directly inhibit PHD activity in
macrophages leading to stabilization of HIF1A(76, 77). Additionally, increased
succinate production can contribute to increased ROS production which can oxidize
PHD cofactors ultimately resulting in the stabilization of HIF1A(77, 78).
Agents or means which have been demonstrated to stabilize HIF1A include siRNA
against FIH and CoCl2, which acts as PHD inhibitor(70, 79). Pharmacologic inhibitors
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of HIF1A include 17-DMAG, an inhibitor of heat shock protein 90 (hsp90), leading to
improper folding of HIF1A, its destabilization and subsequent degradation(80).

HIF1A in Chronic Lung Disease
On history, physical and laboratory examination, IPF patients often
demonstrate features of chronic hypoxia including shortness of breath, reduced
diffusion capacity of the lung and 6 minute walk distance, and decreased partial
pressure of oxygen in arterial blood(2, 81). Increased immunohistochemical staining
for HIF1A on histological evaluation of lungs from IPF patients also supports the
presence of hypoxia(82). Similarly, animal models of bleomycin-induced chronic
pulmonary fibrosis show decreased arterial oxygen saturation and increased HIF1A
in the lungs(83). Weng et al. demonstrated in vitro and in vivo how hypoxia-induced
stabilization of HIF1A contributes to induction of deoxycytidine kinase (DCK) and
subsequent alveolar epithelial cell proliferation contributing to the development of
severe lung fibrosis(84). In vivo inhibition of HIF1A in a house dust mine (HDM) model
of chronic asthma led to decreases in eosinophilia, inflammation, reductions in VEGF
and CXCL1 in association with fewer endothelial progenitor cells and peribronchial
angiogenesis(85). Together these studies illustrate HIF1A contributes to inflammation
and fibrosis in chronic lung disease.

HIF1A in ALI
A role for HIF1A in acute lung injury is only recently being elucidated and is still
unclear depending on the model of lung injury and cell-type involved. HIF1A upregulation in a hypoxia/ischemia reperfusion model led to an increase in VEGF and
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disruptions of the vascular barrier suggesting a tissue-destructive role for HIF1A in
acute injury(72). Similarly, stabilization of HIF1A in neutrophils was revealed to
promote NF- activation, preventing their apoptosis after in vitro hypoxia exposure
suggesting a pro-inflammatory role for HIF1A(86). However, HIF1A-dependent
reduction in adenosine kinase led to an increase in adenosine levels that protected
the vascular barrier(72, 87). Also demonstrating an anti-inflammatory role for HIF1A
in acute injury, a normoxic model of ventilator-induced lung injury (VILI) by mechanical
stretch led to HIF1A stabilization which was associated with reductions in pulmonary
edema and inflammation(88). Alveolar-epithelial cell specific HIF1A deletion however
led to exacerbations of acute lung injury in association with suboptimal carbohydrate
metabolism after VILI emphasizing an anti-inflammatory role for HIF1A in alveolar
epithelial cells(89).

HIF1A and Adenosine Signaling
HIF1A is known to regulate elements of the adenosine pathway. Specifically,
HIF1A has been shown to regulate expression of the ADORA2B receptor, by binding
to the HRE of its promoter, CD73, and equilibrative nucleotide transporters (ENTs)
which allow adenosine transport across the cell membrane (88, 90, 91). This
regulation ultimately leads to elevation of extracellular adenosine levels and
enhancement of ADORA2B signaling.
The promoter of CD73 has also been found to have a HIF1 binding site and in
vivo studies of a mouse model of hypoxia-induced intestinal injury showed CD73
inhibition increased barrier disruption, supporting a protective role for CD73 in
hypoxia-mediated acute injury(92). Cyclic mechanical stretch of pulmonary epithelia
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and in vivo model of VILI has been shown to promote HIF1A stabilization and
significant increases in ADORA2B which were reduced with HIF1A inhibition in vitro
and epithelial-cell specific HIF1A deletion (88). These studies suggest a role for HIF1A
in modulating players in the adenosine signaling pathway that contribute to tissue
protection in acute lung injury.
Most recently, we demonstrated up-regulation of HIF1A along with ADORA2B,
CD73, and ENT-1 in tissue samples from patients with Group 3 pulmonary
hypertension (PH), or PH associated with chronic lung disease, in association with
increased succinate levels, a known HIF1A stabilizer as discussed above(93). As
HIF1A has been shown to regulate ADORA2B expression and ADORA2B has been
found to be elevated and localized to alternatively-activated macrophages in IPF
patients, this dissertation will further investigate the role HIF1A plays on modulating
ADORA2B expression on myeloid cells and macrophage differentiation.

ALTERNATIVELY-ACTIVATED MACROPHAGES (AAMs)
Macrophage Subtypes
Monocytes circulate in the vasculature prior to entering tissues where they
become macrophages, either long-living tissue-specific as residents, or are recruited
to phagocytose and kill infectious agents, scavenge toxins, or act as antigen
presenting cells(94, 95). Therefore, mononuclear cells play a key role in the
inflammatory response and wound repair response in a variety of tissues (48, 94-96).
Macrophages can generally be classified into two larger subtypes: classically
activated and alternatively-activated. Classically-activated macrophages (CAMs) are
activated by Th1 cytokines including TNF, IFN, granulocyte macrophage-colony
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stimulating factor (GM-CSF), PAMPs (i.e. LPS), or DAMPs(48, 74, 96). CAMs produce
inducible nitric oxide synthase (iNOS), TNF, IL-1, and IL-12(96). Their primary
function is pro-inflammatory to contain microbes and tumoricidal and anaerobic
glycolysis predominantes (74, 96).
Alternatively-activated macrophages (AAMs) are polarized by activation with
Th2 cytokines including IL-4 (binds IL-4R activating Signal transduction and activator
of transcription (STAT)6), IL-13 (shares STAT6 signaling), IL-6, IL-10 (activates
STAT3), M-CSF, and MCP-1(74, 96-98). A novel pharmacologic inhibitor of STAT6
signaling is AS1517499 which disrupts IL-4 and IL-13-mediated differentiation of macs
into AAMs(97, 99-101). Mauer et al have demonstrated in a diet-induced obesity
mouse model that IL-6 expression induced IL-4R on macrophages, increasing their
responsiveness to IL-4 and subsequent AAM activation(102).
AAMs predominantly express Arginase-1 and mannose receptor C, or CD206,
along with found in inflammatory zone-1 (FIZZ-1), and chitinase3-like-3 (Ym1).
Arginase-1 is an enzyme which metabolizes arginine to urea and ornithine, which is
subsequently utilized for proline and collagen synthesis thereby contributing to
extracellular matrix (ECM) deposition(48, 96). In fact, Arginase-1 competes with iNOS,
produced by CAMs, for the arginine substrate thereby reducing nitric oxide production
(96). AAMs also utilize oxidative glycolysis and fatty acid oxidation as opposed to
anaerobic pathways(74). CD206 is also a key glycoprotein important to AAM
phagocytosis function by increasing efferocytosis of pathogens and apoptotic
cells(103).
Ultimately, AAMs regulate wound healing through release of matrix degrading
enzymes and growth factors, and lead to fibrosis by stimulating myofibroblast
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activation, proliferation, and survival(94, 95, 98). Flow cytometry analysis of lung
macrophages after a bleomycin-model of lung injury reveal during initial stages or at
rest, markers which predominate are CD11c+CD11b- indicative of resident
macrophages however in later stages of injury after fibrosis development, a majority
of macrophages are recruited macrophages, or CD11c+CD11b+(104). Additional
functions of AAMs including protection from parasites and suppression of the Th1
response(74). TNF treatment of bleomycin exposed mice led to reductions in fibrosis
and AAM expression supporting a role for AAMs in the development of lung fibrosis
and the potential of encouraging macrophage switch to CAMs as a possible
treatment(105). AAMs have been found to be a regulatory effector cell type involved
in remodeling in many diseases including asthma, COPD, CF, and liver fibrosis(95).

Adenosine and Macrophages
There is evidence that the key effector cell type influenced by ADORA2B
receptor signaling in pulmonary fibrosis is the lung macrophage. Lung macrophages
increase over time in animal models of fibrosis(106). Previous work by our lab has
shown that IPF patients have increased ADORA2B receptor positive alternatively
activated macrophages (AAM) and we have also shown that the presence of the
ADORA2B receptor on these macrophages is critical to the production of pro-fibrotic
cytokines such as interleukin-6 (IL-6)(55, 56). In support of a pro-fibrotic and AAM
promoting role for ADORA2B in another chronic lung disease, global and myeloidspecifc ADORA2B deletion in a cockroach allergen mouse model of asthma led to
reductions in inflammatory cell infiltration, airway mucin production, and decreased
secretion of pro-inflamamtory cytokines including TNF, tm, and IL-17(107). Th2
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cytokines IL-4, IL-5, and IL-13 were also reduced demonstrating ADORA2B on
myeloid cells as a regulator of a Th2 rich environment in the development of chronic
inflammation in asthma (107). Additionally, Csoka et al have indicated a role for the
ADORA2B receptor, and to a lesser extent, ADORA2A, in mediating differentiation of
macrophages into the AAM phenotype (108).
Like ADORA2B, the other adenosine receptors have also been found to affect
macrophage differentiation and function. Adenosine itself has been shown to stimulate
IL-10-induced STAT3 signaling and subsequent activation of M2c macrophages(109).
Activation of ADORA1 on monocytes leads to differentiation of multinucleated giant
cells(48). Both ADORA2A and ADORA2B have been found to be pivotal to
macrophage metabolism as they can increase Specificity protein (Sp1) expression
promoting increase in glycolytic flux, a metabolic shift believed to play a role in shifting
CAMs to AAMs(48). Moreover, there is significant evidence that ADORA2B drives
differentiation of AAM, however this dissertation seeks to delineate the disease signals
which drive this response whether it be Th2-cytokine-STAT6 mediated or hypoxia
through HIF1A.

HIF1A and Macrophages
Hypoxia in the setting of inflammation has been observed to cause significant
changes in functional plasticity of macrophages, which account for 95% of the
recruited cells(74). Changes observed in gene expression include up-regulation of
VEGF, MMP7, MMP9, and M2 markers such as Arginase-1(96, 110). Cramer et al
demonstrate that HIF1A deletion on myeloid cells leads to depletion of the ATP pool
which is associated with poor myeloid cell invasion, motility, and bactericidal abilities
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suggesting that HIF1A can directly impact macrophage metabolism and subsequent
survival and function in the setting of inflammation(110). HIF1A-/- macrophages have
reductions in bactericidal activity, angiogenesis, worsened systemic infection, and
reduced TNF and IL-6 responses(111). Hypoxia through HIF1A in T lymphocytes
has been shown to promote the shift of cells from T helper 1 (Th1) to T helper 2 (Th2);
this shift in the T helper cell environment can directly influence cytokines released into
the extracellular environment and mediate macrophage differentiation as discussed
above(112). Limited studies so far suggest that HIF1A in myeloid cells affects
macrophage metabolism, function, and gene expression suggestive of an AAM
subtype, however the mechanisms by which HIF1A mediates changes in macrophage
differentiation and subsequent fibrosis development remain to be understood and will
be investigated in this dissertation.

DISSERTATION OVERVIEW
IPF is a common, chronic disease which significantly impacts the quality of life
of millions of individuals worldwide(2). Median survival after diagnosis is typically 3-5
years due to the absence of any effective therapies outside of lung transplantation(26).
The incidence and prevalence of IPF continues to rise hastening the need to better
understand the pathways which mediate the development and progression of
pulmonary fibrosis(5). We have previously demonstrated a role for the signaling
molecule adenosine in the setting of acute or chronic lung injury and demonstrated its
elevation in patients with IPF and animal models of bleomycin-induced lung injury(56).
Activation of ADORA2B by extracellular accumulation of adenosine can lead to
features of chronic lung disease including inflammation, fibrosis, and tissue
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remodeling(56). We have shown previously the increase in expression of ADORA2B
and AAMs which are correlated with increased pro-fibrotic mediator production(55,
65). The stabilization of HIF1A has been found to up-regulate ADORA2B however its
role as a direct modulator of macrophage phenotype remains to be understood (88).
Additionally, factors which regulate adenosine receptor expression on alternatively
activated macrophages and their role in IPF are unknown. An understanding of AAMs
and previous work demonstrating a pro-fibrotic role for ADORA2B receptor led to the
development of my proposed project which investigates the hypothesis that both
hypoxia and lung macrophage differentiation contribute to the progression of
pulmonary fibrosis through up-regulation of ADORA2B; and myeloid-specific
ADORA2B deletion or HIF1A inhibition in late stages of disease will attenuate
fibrosis.

Specific Aim 1: Evaluate the expression and regulation of ADORA2B on AAMs
and determine the role of ADORA2B on AAMs in pulmonary fibrosis.
Conditional knockout mice lacking ADORA2B receptor on myeloid cells
(ADORA2Bf/fLysMCre) were exposed to the intraperitoneal bleomycin injections over
33 days. ADORA2Bf/fLysMCre after bleomycin treatment showed evidenced of
improved arterial oxygen saturation and decreased fibrosis consistent with the
presence of fewer AAMs as compared to wild type mice after bleomycin exposure
(113). To validate these findings in vitro, BMDMs were isolated from C57Bl6 and
ADORA2B-/- mice, treated with Th2 cytokines and hypoxia in addition to panadenosine receptor agonist, with and without ADORA2B antagonist, to evaluate the
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effect on AAM and CAM expression along with pro-fibrotic molecule production.
BMDMs were also utilized to determine the effect of Th1 in comparison to Th2 cytokine
treatment on adenosine receptor expression. Results of this aim are presented in
Chapter 3.

Specific Aim 2: Evaluate the expression of HIF1A in AAMs and determine the
effect of HIF1A inhibition in pulmonary fibrosis.
HIF1A stabilization and localization to AAMs in addition to ADORA2B
expression was characterized in lung sections from patients with IPF. To demonstrate
HIF1A stabilization in AAMs in a mouse lung sections, Hif1-luciferase reporter mice
were then exposed to bleomycin. A HIF1A pharmacologic inhibitor, 17-DMAG, was
then delivered in late stages of bleomycin-induced lung injury in C57BL/6 mice to
evaluate the role of HIF1A inhibition on ADORA2B expression, macrophage
differentiation, and the development of fibrosis. Finally, BMDMs from control mice
were cultured in the presence of a HIF1A stabilizer, inhibitor, STAT6 inhibitor, along
with genetic silencing to establish the role of HIF1A as a driver of ADORA2B
expression on macrophages, mediating their differentiation into the AAM subtype, and
promoting production of pro-fibrotic molecules and the subsequent development of
pulmonary fibrosis. Chapter 4 discusses the results of this aim.

Specific Aim 3: Evaluate the role of HIF1A on myeloid cells in lung injury.
Myeloid-specific HIF1A knockout mice (HIF1Af/fLysMCre) were exposed to
bleomycin-induced lung injury to evaluate the role of HIF1A in acute and chronic
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stages of disease. A time course experiment of varying degrees of bleomycin
exposure reveal an anti-inflammatory role for HIF1A in acute lung injury. Evaluation
of fibrotic markers in later stages of disease reveal exacerbations in fibrosis despite
HIF1A-mediated reductions in ADORA2B and AAM expression. BMDMs from
HIF1Af/fLysMCre mice were stimulated in culture with Th2 cytokines, hypoxia, and
adenosine receptor agonist to establish the effect HIF1A deletion on myeloid cells
places in regulation of ADORA2B and macrophage differentiation.
Insight into the mechanisms contributing to the development and progression
of fibrosis in IPF will lead to direct development of novel therapies which target key
pathways and cells included in this project such as ADORA2B antagonists or HIF1A
inhibitors which modulate macrophage phenotype, pro-fibrotic mediator production,
and the development of lung fibrosis.
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CHAPTER TWO
EXPERIMENTAL PROCEDURES
Human Subjects
Explanted lung tissue samples from healthy, normal (n=6) and IPF patients
(n=19) were de-identified and obtained from the International Institute for the
Advancement of Medicine (IIAM, Edison, NJ) and the Methodist Hospital J.C. Walter
Jr. Transplant Center (Houston, TX), respectively (Table I). These lung tissue are
those normal or affected lungs that come from lung transplants or lungs gathered but
not used for transplants. IIAM and Methodist Hospital Institutional Review Board
guidelines were strictly adhered to for tissue collection and use.

Table I. Distribution of demographic and clinical variables for patient
population.

Gender, n (%)
Males
Females
Age (Mean ± SD)
Overall
Males
Female
BMI (Mean ± SD)
PaO2, mmHg (Mean ± SD)
PaCO2, mmHg (Mean ± SD)
mPAP , mmHg (Mean ± SD)
Systolic PAP, mmHg (Mean ± SD)
Diastolic PAP, mmHg (Mean ± SD)
6MWD, feet (Mean ± SD)
FVC, % (Mean ± SD)
DLCO, % (Mean ± SD)
FEV1, % (Mean ± SD)

Normal
(n=6)

IPF
(n=19)

p-value

1 (16.67)
5 (83.33)

12 (63.2)
7 (36.8)

0.00410
0.04362

43.6 ± 17.07
63
38.75 ± 15.22
29.46 ± 5.50
138.68 ± 60.44
37.1 ± 9.20

63 ± 9.22
67 ± 7
56 ± 9.45
28.69 ± 6.24
72.23 ± 29.11
40.29 ± 6.22
18.95 ± 6.47
30.63 ± 10.36
13.16 ± 5.12
795.24 ± 458.77
54 ± 24
29.06 ± 10.94
7.99 ± 3.80

0.06314
0.08801
0.09926
0.79276
0.07121
0.49692

Abbreviations: mPAP = mean pulmonary arterial pressure; PAP = pulmonary arterial
pressure; 6MWD = six-minute walk distance; BMI = body mass index; FVC = forced vital
capacity; DLCO = diffusing capacity of the lung for carbon monoxide; TLC = total lung
capacity; FEV1 = forced expiratory volume in one second; PaO2 = = partial pressure of
oxygen in arterial blood; PaCO2 = partial pressure of carbon dioxide in arterial blood.
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Generation and Genotyping of Mouse Lines
All inbred, male, 5-6 week old C57BL/6 and LysMCre mice were obtained from
Harlan (Envigo) Laboratories (Houston, TX). ADORA2Bf/fLysMCre, HIF1Af/fLysMCre,
and Hif1::LUC reporter mice (FVB.129S6-Gt(ROSA)26Sor tm2(HIF1AA/luc)Kael/J)
were obtained from Holger K. Eltzschig(89). DNA was extracted from tail
samples to confirm genotypes with PCR. Animals were maintained and cared
for in agreement with McGovern Medical School at University of Texas Health
Sciences Center Animal Welfare Committee (AWC) guidelines. Study designs were
approved by AWC.

Intraperitoneal Bleomycin Mouse Model
Bleomycin is a glycopeptide chemotherapeutic antibiotic used to treat different
types of cancer including testicular cancer and Hodgkin’s lymphoma (114). 10% of
patients treated develop pulmonary toxicity secondary to reduced levels of the enzyme
bleomycin hydrolase, responsible for its inactivation (114). Thus, repeated bleomycin
exposure contributes to inflammation and the subsequent development of pulmonary
fibrosis(114). Ultimately, bleomycin leads to breaks in the DNA strand contributing to
the production of ROS(115). C57BL/6 mice are more susceptible to bleomycininduced injury and demonstrate increased inflammation in the first 14 to 21 days
followed by the development of fibrosis by day 20 onwards in an intraperitoneal model
(56, 115). This model however is limited in that the fibrosis that develops is reversible
once systemic bleomycin administration is stopped (115). Despite this limitation, the
bleomycin-induced model of lung injury is more frequently used than exposure to
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silica, fluorescein isothiocyanate (FITC), or irradiation as it better models features
observed in patients with IPF including the presence of hyperplastic epithelial cells,
greater concentration of pleural fibrotic patches, and the fibrosis development is
progressive (49, 116).
Utilizing this model, male, 5-6 weeks old, C57BL/6, ADORA2Bf/fLysMCre,
HIF1Af/fLysMCre, LysMCre, and Hif1::LUC reporter mice were treated with 8
intraperitoneal bleomycin (0.035U/g, Teva Pharmaceutical, Irvine, CA) or saline
injections, twice a week over a four week period as described previously (Figure
2.1A,B,C) (83, 113). HIF1Af/fLysMCre and LysMCre mice were sacrificed and samples
collected on day 3, 7, 14, 20, and 33. ADORA2Bf/fLysMCre, LysMCre, and C57BL/6 were
sacrificed and samples collected at the following time points after bleomycin or saline
exposure: 14, 17, 20, 21, 25, and 33. Samples from Hif1::LUC reporter mice were
collected on day 33.

In vivo Inhibition of HIF1A 
In

vivo

inhibition

of

HIF1A

was

carried

out

using

17-

(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG, InvivoGen, San
Diego, CA). Male, 5-6 week old C57BL/6 mice were treated with intraperitoneal
bleomycin or vehicle control (saline) twice a week for 33 days. Beginning on day 20
and every other day until day 33, mice were treated with saline (100L 1X sterile PBS)
or 25mg/kg 17-DMAG(117). Mice received 17-DMAG injections 3-4 hours before
bleomycin on treatment days were both were to be given. Arterial oxygen saturation
levels were measured on day 33 prior to animal sacrifice and sample collection.
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Figure 2.1. Intraperitoneal (i.p.) bleomycin model of pulmonary fibrosis. 8
intraperitoneal bleomycin (0.035U/g, Teva Pharmaceutical, Irvine, CA) or saline
injections are administered twice a week over a four week period in the i.p. bleomycin
model. (A) In Chapter 3, samples were collected at day 14, 17, 21, 25, and 33 from
ADORA2Bf/fLysMCre, LysMCre, and C57BL/6 mice exposed to bleomycin or PBS. (B)
17-DMAG, an inhibitor of HIF1A, was administered every other day from day 20
onwards to evaluate the impact of HIF1A inhibition on fibrosis development in Chapter
4. (C) HIF1Af/fLysMCre and LysMCre mice were sacrificed and samples collected on day
3, 7, 14, 20, and 33 in Chapter 5. (Red arrows indicate sacrifice and sample collection
days).
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Assessment of Arterial Oxygen Saturation
Mice were shaved along the neck and awake for arterial oxygen saturation
measurement on day 33 using the Pulse MouseOx software (STARR Life Sciences
Corp, Oakmount, PA).

Plasma, Bronchoalveolar lavage fluid (BALF), Cellular differentials, and
Histology
Once mice were anesthetized with Avertin, blood was collected and centrifuged
to collect plasma. Lungs were lavaged four times with 0.3mL PBS to collect BALF. A
hemocytometer was used to determine total cell counts. Aliquots of BAL cells spun
onto microscope slides and stained with Diff-Quick (Dade Behring, Deerfield, IL) were
used to assess cellular differentials. BAL fluid remaining was centrifuged and cell
pellet and supernatant were stored for further analysis. Once BALF was collected,
lungs were pressure inflated, fixed in 10% formalin, and embedded in paraffin. 5m
lung sections were used for immunostaining and further histological analysis.

Immunohistochemistry and Immunofluorescence
Immunohistochemistry was performed on 5m sections from formalin-fixed,
paraffin-embedded lungs. Antigen retrieval was performed on rehydrated sections
using Tris-based Antigen Unmasking Solution (Vector Laboratories) followed by
blocking of endogenous avidin and biotin using the Biotin-Blocking system (Vector
Laboratories, Burlingame, CA), Bloxall (Vector Laboratories) for 30 minutes, and
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normal horse serum (Vector Laboratories) for 1 hour at room temperature. Nuclear
permeabilization with 1% Triton-X 100 was also carried out for 10 minutes after
antigen retrieval and prior to blocking for anti-HIF1A and anti-firefly luciferase staining.
Slides for immunohistochemistry were incubated with anti-SMA (1:1000 mouse
monoclonal; Sigma-Aldrich), anti-CD206 (1:100 rabbit polyclonal; Bioss) , anti-iNOS
(1:100 rabbit polyclonal; Abcam Inc.), anti-IL-6 (1:100 rabbit polyclonal; Abcam Inc) ,
or anti-Ly6.b (1:500 rat anti-mouse; AbD SeroTec) overnight at 4C and developed
the following day with the ImmPRESSTM-AP Anti-Rabbit IgG (Alkaline Phosphatase)
Polymer Detection Kit (Vector Laboratories) prior to counterstaining with
haematoxylin, dehydration, and mounting with coverslip.
Dual immunofluorescence staining of F4/80 and CD206 began with primary
antibody incubation for CD206 (1:100 rabbit polyclonal; Bioss) overnight at 4C,
development with Vector Red, followed by incubation with F4/80 (1:500 rat polyclonal;
Acris Antibodies) and development with goat anti-rat Alexa Fluor-488 (1:500; Life
Technologies). For immunofluorescence staining of alpha smooth muscle actin
(SMA), slides were incubated with Cy3-conjugated mouse monoclonal anti-SMA
(1:1000; Sigma-Aldrich) overnight at 4C, prior to mounting with with Vectashield
Antifade

Mounting

Medium

with

DAPI

(Vector

Laboratories).

For

dual

immunofluorescence of HIF1A and CD206, slides were incubated in antiHIF1A(1:200 rabbit polyclonal; Bethyl Laboratories Inc.) overnight at 4C and then
developed using the ImmPRESSTM-AP Anti-Rabbit IgG (Alkaline Phosphatase)
Polymer Detection Kit described above (Vector Laboratories). Slides were next
incubated in anti-CD206 (1:100 rabbit polyclonal; Bioss) overnight at 4C prior to
secondary incubation with Alexa 633 goat anti-rabbit (1:500; Life Technologies) and
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mounting with Vectashield Antifade Mounting Medium with DAPI (Vector
Laboratories). Dual immunofluorescence staining of Firefly Luciferase and CD206
began with primary antibody incubation with Cy3-conjugated anti-firefly luciferase
(1:1000 rabbit polyclonal; abcam) overnight at 4C, followed by blocking and
incubation with anti-CD206 (1:100 rabbit polyclonal; Bioss) overnight at 4C.
Secondary incubation with Alexa 633 goat anti-rabbit (1:500; Life Technologies) was
carried out at room temperature the next day followed by incubation with sudan black
for 10 minutes, copper sulfate for 10 minutes, and Levisamole (Vector Laboratories)
for 5 minutes to quench any autofluorescence and mounting with DAPI (Vector
Laboratories).

Immunofluorescence of BAL cells
Cytospun BAL cells from Hif1::LUC reporter mice after saline or bleomycin
exposure, described above, were air-dried, fixed with 3.7% paraformaldehyde for 10
minutes, followed by permeabilization in cold methanol for 10 minutes, and nuclear
permeabilization with 1% Triton-X 100 for 10 minutes. Endogenous avidin and biotin
were blocked with the Biotin-blocking kit (Vector Laboratories), followed incubation
with Bloxall (Vector Laboratories) for 10 minutes, and normal horse serum (Vector
Laboratories) for 20 minutes at room temperature. Slides were then incubated over
night at 4C with Cy3-conjugated anti-firefly luciferase (1:500, rabbit polyclonal,
Bioss). After washing with TBS-T, slides were blocked again with Bloxall and normal
horse serum (Vector Laboratories) before incubation with anti-CD206 (1:500, rabbit
polyclonal, Bioss) overnight at 4C. The following day, slides were incubated with
secondary antibody, Alexa Fluor 633 goat anti-rabbit (1:500; Life Technologies) for
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one hour at room temperature in the dark. Slides were mounted with coverslip and
Vectashield Antifade Mounting Medium with DAPI (Vector Laboratories).

Assessment of Fibrosis
Masson’s trichrome collagen staining was performed according to the
manufacturer’s instructions on rehydrated lung sections (EM Science, Gibbstown,
NJ). A modified Ashcroft scoring method was used to quantify fibrosis among stained
slides (118). Slides were blinded to reviewers with respect to treatment group. Soluble
collagen content in BALF was measured using the Sircol assay (Biocolor Ltd., Carrick,
UK). Whole lung RNA was used to quantify collagen transcripts and whole lung protein
lysates utilized for determining fibronectin expression.

Western Blot Analysis
Mouse lung tissues were pulverized or cells from bone marrow-derived
macrophages in culture were lysed in RIPA lysis buffer (50mM Tris-HCL pH 7.4, 150
mM NaCl, 1% NP-40) containing a protease inhibitor cocktail to extract protein
(Thermo Fisher Scientific, Waltham, MA). Equal amounts of protein were separated
on SDS-PAGE and transferred to PVDF membranes (GE Healthcare, Life Sciences,
Pittsburgh, PA). Membranes were blocked for 1 hour at room temperature with 5%
nonfat milk and then washed with Tris-buffered saline-Tween-20 and incubated with
primary HIF1A (1:500 rabbit polyclonal; LifeSpan Biosciences), ADORA2B (1:1000
rabbit polyclonal; LifeSpan Biosciences), CD206 (1:250 rabbit polyclonal; Bioss),
fibronectin (1:1000 rabbit polyclonal; Sigma-Aldrich), collagen I (1:1000 rabbit
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polyclonal; abcam), -actin (1:1000 rabbit polyclonal) overnight at 4C. Washed
membranes were incubated with corresponding secondary antibodies conjugated to
horseradish peroxidase (Cell Signaling Technology, Danvers, MA, USA) for 1 hour at
room temperature and developed with Amersham ECL Prime Western Blotting
Direction Agent (GE Healthcare, Life Sciences) or Pierce ECL Western Blotting
Substrate (Thermo Fisher Scientific).

Analysis of whole lung and BAL cell pellet RNA
RNA was isolated from frozen lung tissue, bronchoalveolar lavage cell pellet,
or macrophage cell lysate using TRIzol (Invitrogen) as per manufacturer’s instructions.
cDNA was synthesized using the iScriptTM cDNA synthesis kit (BioRad) and equal
amounts were analyzed for transcript levels of COL1A1, COL1A2, ARG-1, ADORA2B,
NOS2, IL-6, and CXCL1 with normalization to beta actin or 18s rRNA. Primers for
COL1A1

were

forward

5’-GCTCCTCTTAGGGGCCACT-3’

CCACGTCTCACCATTGGGG-3’.

Primers

for

COL1A2

and
were

reverse

5’-

forward

5’-

AAGGGTGCTACTGGACTCCC-3’ and reverse 5’-TTGTTACCGGATTCTCCTTTGG3’. Primers for ARG-1 were forward 5’-CAGAAGAATGGAAGAGTCAG-3’ and reverse
5’-CAGATATGCAGGGAGTCACC-3’. Primers for ADORA2B were forward 5’GCGTCCCGCTCAGGTATAAAG-3’
CGGAGTCAATCCAATGCCAAAG-3’.

and
Primers

for

5’-

reverse
NOS2

were

forward

5’-

GTTCTCAGCCCAACAATACAAGA-3’ and reverse 5’-GTGGACGGGTCGATGTCA3’. Primers for IL-6 were forward 5’-TAGTCCTTCCTACCCCAATTTCC-3’ and reverse
5’-TTGGTCCTTAGCCACTCCTTC-3’.

Primers

for

CXCL1

were

forward

5’-

CTGCACCCAAACCGAAGTC-3’ and reverse 5’-AGCTTCAGGGTCAAGGCAAG-3’.
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Primers for MCP-1 were: forward 5’-TCAGCCAGATGCAGTTAACGC-3’ and reverse
5’-TGATCCTCTTGTAGCTCTCCAGC-3’. Next, the comparative Ct method was used
to present data as mean normalized transcript levels.

Quantification of Protein in Bronchoalveolar Lavage Fluid
IL-6 levels in BALF from C57BL/6 and ADORA2Bf/fLysMCre mice after
bleomycin or PBS treatment was quantified using the murine IL-6 ultrasensitive kit
(Meso Scale Discovery) and read on the Sector Imager 2400 (Meso Scale Discovery)
per manufacturer’s protocol. Collagen levels were assessed in BALF from C57BL/6
mice after PBS or BLM exposure ± 17-DMAG on day 33 utilizing the BioColor kit per
manufacturer’s instructions. The Mouse ELISA Kit from Immunology Consultants
Laboratory was used to quantify albumin levels and Hycult Biotech ELISA Kit to
assess MPO levels in BALF from HIF1Af/fLysMCre and LysMCre mice after PBS or BLM
exposure on day 3 and 7.

Dual-luciferase Assay
Whole lung lysate and BALF from Hif1::LUC reporter mice after saline or
bleomycin treatment was prepared for luciferase activity measurement per
manufacturers protocol (Dual-Luciferase Reporter Assay System, Promega
Corporation, Madison, WI). Briefly, samples were diluted in Passive Lysis Buffer (PLB,
Promega), protein concentration measured using the PierceTM BCA Protein Assay Kit
(ThermoFisher Scientific), and samples were diluted to 0.5g/uL of PLB in a 96-well
plate. Equal volumes of Luciferase Assay Reagent II (LAR, Promega) were added to
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each well prior to measurement of Firefly luciferase activity, followed by addition of
equal volumes of Stop & Glo Reagent (Promega) to each well and Renilla luciferase
activity. Data are presented as relative luciferase activity, or Firefly luciferase to
Renilla luciferase activity.

Bone Marrow Macrophage Isolation and Differentiation
Bilateral femurs were isolated from male C57BL/6 mice (5-6 wk old, inbred,
Envigo Laboratories). Complete macrophage medium, DMEM (Fisher Scientific)
supplemented with 10% FBS and 20% L929 media supplement was next used to flush
the marrow cavity. L929 media supplement was made by seeding L929 cells at a
density of 5x105 cells per T75 flask in 55mL media of DMEM with 1% HEPES, 1%
penicillin-streptomycin, 1% L-glutamine, and 10% FBS. L929 cells were then cultured
for 7 days and harvested media was sterile filtered for addition to macrophage culture
media. Bone marrow cells were pelleted, resuspended in complete macrophage
media and plated in 100mm bacterial dishes at a density of 5x106 cells in 10mL media
per dish. Cells were incubated at 37°C, 5% CO2 for 4 days and then supplemented
with 5mL of media. On day 7, adherent bone marrow-derived macrophages were
detached, collected, pelleted, and resuspended in macrophage media for seeding in
six-well tissue culture plates at a density of 1.5x106 cells/mL and allowed to adhere
for 2-3h. Adherent cells were then incubated in macrophage media with and without
20ng/mL Interleukin 4 (IL-4) and 10ng/mL Interleukin-13 (IL-13) (Peprotech, Rocky
Hill, NJ) for three days with addition of fresh cytokines daily or 100ng/mL LPS (Sigma)
and 30ng/mL IFN(PeproTech) for 24 hours. Macrophages were washed and used
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for ADORA2A, ADORA2B, STAT-6, and HIF1A stimulation and antagonism
experiments (Figure 2.2).

Figure 2.2 Bone marrow derived macrophages isolation, culture, and treatment.
Bone marrow (BM) cells were isolated from femurs of C57BL/6 (A,B), (A) ADORA2A /-,

ADORA2B-/-, HIF1Af/fLysMCre, and LysMCre mice and cultured with L929-

supplemented media for 7 days. In Chapter 3 (denoted (3)), these macrophages were
then treated with (A) 10ng/mL IL-4 and 10ng/mL IL-13 for 72 hours or (B) 100ng/mL
LPS and 30ng/mL IFN for 24 hours followed by 12 hour 2% O2 exposure alongside
treatment with NECA ± MRS1754 and NECA ± ZM241385. In Chapter 4 (4), C57BL/6
BMDMs were treated with CoCl2 ± 17-DMAG at time 0hr or double-transfected with
control or siRNA against HIF1A on -2d and -1d prior to hypoxia exposure. In Chapter
5 (5), HIF1Af/fLysMCre and LysMCre BMDMs were treated with NECA and C57BL/6
BMDMs were double transfected with control siRNA, siRNA against HIF1A and HIF2A
on -2d and -1d. Cells were lysed and RNA and protein collected at 12hours (12h).
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Primary Lung Macrophage and Isolation
Mouse lungs from male C57BL/6 mice exposed to bleomycin over 33 days, as
described above, were isolated and treated with 1 to 2mL Dispase (BD Bioscience,
San Jose, CA, USA) and immediately stored on ice. The lungs were then incubated
in 2mL Dispase at room temperature for 45 minutes, diced into 1mm cubes and filtered
through 100m, 40m, and a 25m nylon mesh. Filtered cells were incubated in an
IgG plate for 45 minutes at 37C in lung macrophage media (RPMI 1640 (Fisher
Scientific), 10% FBS, and 1% penicillin/streptomycin) to select for macrophages. Cells
were washed in fresh macrophage media to remove detached cells or other cell-types
and allow for macrophages to settle prior to treatment with CoCl2 and 17-DMAG.

Stimulation and Antagonism of Adenosine Receptors, STAT-6, AND HIF1A in
Macrophages
Bone marrow-derived macrophages treated with and without IL-4/IL-13 for 72
hours, were next incubated in serum-free media for up to 12 hours. Macrophages were
pre-incubated with Adenosine deaminase (PEG-ADA; Roche) to inhibit endogenous
adenosine activity prior to 12 hour hypoxia exposure, 2% O2, and treatment with 10m
1-(6-Amino-9H-purin-9-yl)-1-deoxy-N-ethyl--D-ribofuranuronamide (NECA, Tocris
Bioscience, Minneapolis, MN) or 1m Bay 60-6085 (Tocris Bioscience, Minneapolis,
MN) with and without 1m N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3dipropyl-1H-purin-9-yl)phenoxy]-acetamide

(MRS

1754,

Tocris

Bioscience,

Minneapolis, MN) to stimulate and antagonize ADORA2B; 10M ZM241385 (Tocris
Bioscience) to stimulate and antagonize ADORA2A; 100nM AS 1517499 (axon
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MEDCHEM, Netherlands) to inhibit STAT-6; 3m 17-DMAG with and without 100m
CoCl2 (Sigma-Aldrich) to stabilize and antagonize HIF1AAfter 12 hours exposure
with the above treatments, macrophages were lysed in RIPA lysis buffer (20g of
protein per sample) or TRIzol (Invitrogen) for western blot and RNA analysis,
respectively.

HIF1A and HIF2A Small Interfering RNA Silencing in Macrophages
Bone marrow derived macrophages from day 7-8 were resuspended in
antibiotic-free macrophage media, seeded in 6-well plates, and allowed to adhere for
2-3 hours. Macrophages were then incubated in media containing IL-4, IL-13,
Optimem (Invitrogen) with Lipofectamine RNAiMax (Invitrogen), HIF1A siRNA and or
HIF2A siRNA, or scrambled control siRNA (Sigma-Aldrich) for 24 hours. Final
concentration of siRNA was 100nM. 24 hours later, media was changed and the
transfection was repeated with fresh reagents for another 24 hours prior to hypoxia
exposure (2% O2) for 12 hours. Cells were lysed in RIPA lysis buffer with protease
inhibitors for western blot analysis (20g of protein per sample) or TRIzol reagent
(Invitrogen) and processed for RNA analysis as described above.

Statistical Analysis
Experiments were repeated at least two times with biological and technical
duplicates at minimum. One-way ANOVA was used for comparisons among multiple
groups. Unpaired, two-tailed Student’s t-test was used for comparisons between two
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groups. A p-value of less than or equal to 0.05 was considered statistically significant.
All statistical analyses were performed with GraphPad Prism 6.0 software (La Jolla,
CA).
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CHAPTER THREE
ADORA2B ON MYELOID CELLS CONTRIBUTES TO THE DEVELOPMENT OF
PULMONARY FIBROSIS
INTRODUCTION
Note: This chapter is based upon: Karmouty-Quintana H., K. Philip, L.F. Acero, N.Y.
Chen, T. Weng, J.G. Molina, F. Luo, J.Davies, N.B.Le, I. Bunge, K.A. Volcik, T.T. Le,
R.A. Johnson, Y.Xia, H.K. Eltzschig, and M.R. Blackburn. 2015. Deletion of ADORA2B
from myeloid cells dampens lung fibrosis and pulmonary hypertension. FASEB
journal: official publication of the Federation of American Societies for Experimental
Biology 29: 50-60. http://www.fasebj.org/content/29/1/50.full Copyright permission
granted 06 Feb 2017 for FJ 14-260182.

Adenosine Signaling on AAMs in IPF
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease which
affects up to 8 million individuals worldwide (2-4). Despite its significant prevalence,
little is known about the mechanisms that lead to the development and progression of
IPF(15). There are few effective treatments for IPF and the five year survival rate
among patients with IPF is only 43%(28). Prognosis in IPF patients is poor secondary
to few effective long-term therapies. As such, there is a significant need to better
understand the pathogenesis of IPF in order to develop novel pharmaceutical
therapies to prevent and reverse this disease.
Previous work suggests that pulmonary fibrosis results from an abnormal tissue
reparative response(53). Evidence suggests that the nucleoside adenosine plays a
critical role in the regulation of this response in the lung and contributes to fibrosis (52,
55, 119). Adenosine levels are elevated in patients with IPF and mouse models of
lung injury in association with increased inflammation and fibrosis(55, 56). Chronic
adenosine accumulation and subsequent activation of ADORA2B can lead to features
63

of chronic lung disease including inflammation, fibrosis, and tissue remodeling (56).
There is evidence that the key effector cell type influenced by ADORA2B receptor
signaling in pulmonary fibrosis is the pro-fibrotic AAM subtype, typically activated by
Th2 cytokines, IL-4 and IL-13 (94, 113). Recent work also suggests ADORA2B
mediates differentiation of macrophages into the AAM phenotype (48, 108).

Experimental Rationale
Previous work by our lab has shown that IPF patients have increased ADORA2B
receptor positive alternatively activated macrophages (AAM) and we have also shown
that the presence of the ADORA2B receptor on these macrophages is critical to the
production of pro-fibrotic cytokines such as interleukin-6 (IL-6)(55, 56). In this chapter,
a myeloid-specific ADORA2B knockout mice is exposed to bleomycin along with bone
marrow-derived macrophages to investigate the hypothesis that ADORA2B on
myeloid cells mediates differentiation of macrophages into the AAM subtype,
increases pro-fibrotic mediator production, and the subsequent development and
progression of pulmonary fibrosis.

RESULTS
Deletion of ADORA2B on myeloid cells attenuates pulmonary fibrosis in
association with improved arterial oxygen saturation
We have previously demonstrated an increase in ADORA2B-expressing AAMs
in patients with IPF, however the role of this receptor on myeloid-cells in contributing
to pulmonary fibrosis remains to be understood (55). As such, we utilized the well64

established intraperitoneal bleomycin model of chronic lung disease to evaluate how
genetic deletion of ADORA2B on myeloid cells would impact the development of
fibrosis. C57BL/6, LysMCre, and ADORA2Bf/fLysMCre mice were treated with intraperitoneal bleomycin or saline for 14, 17, 21, 25, and 33 days. On day 33, whole lung
lysate and lung sections were isolated to assess fibrotic markers. Fibronectin protein
expression (Figure 3.1 A,B) were increased in C57BL/6 exposed to bleomycin but
reduced in myeloid-specific ADORA2B knockout mice after bleomycin exposure.
Collagen 1A2 transcript levels, another marker of fibrosis, was increased after
bleomycin exposure in control mice but significantly reduced in mice lacking
ADORA2B

on

myeloid

cells

treated

with

bleomycin

(Figure

3.1C).

Immunohistochemistry of lung sections for alpha-smooth muscle actin (SMA), a
marker of myofibroblasts, demonstrated an increase in myofibroblasts after bleomycin
exposure which was attenuated in ADORA2Bf/fLysMCre after bleomycin treatment
(Figure 3.1D). Masson’s Trichrome staining for collagen in whole lung sections was
also decreased in ADORA2Bf/fLysMCre mice after bleomycin exposure as compared
to wild-type control mice, C57BL/6, after 33 days of bleomycin treatment; the Ashcroft
scoring method was used to quantify these histologic findings over multiple lung
sections from each treatment group (Figure 3.2A,B).
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Figure 3.1. Myeloid-specific ADORA2B deletion attenuates fibrotic markers on
day 33 after BLM or PBS exposure. [Adapted from Figure 1 of (113)]. (A)
Immunoblot for fibronectin and -actin in whole-lung lysates from C57BL/6 mice
treated with PBS or BLM and ADORA2Bf/fLysMCre mice treated with BLM with
densitometry analysis (B). (C) Col1A2 mRNA expression levels from C57BL/6 mice
treated with PBS or BLM or ADORA2Bf/fLysMCre mice exposed to PBS or BLM. D)
Immunohistochemistry for alpha-smooth muscle actin (SMA) with Gill’s hematoxylin
counterstain from formalin-fixed paraffin-embedded (FFPE) lung sections from
ADORA2Bf/fLysMCre mice exposed to PBS (left), C57BL/6 mice exposed to BLM
(middle),or ADORA2Bf/fLysMCre mice treated with BLM (right). (Positive staining for
SMA is red/pink; Black arrows point at fibroblasts positive for SMA.) (A-C) Used
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with permission from Ning-Yuan Chen and Harry Karmouty-Quintana who performed
immunoblot, PCR, and assembled data, respectively.

***P

≤ 0.001, ANOVA

comparisons between C57BL/6 + PBS and C57BL/6 + BLM treatment groups. #P ≤
0.05 and

##0.001,

P ≤ 0.01, ANOVA comparisons between C57BL/6-BLM and

ADORA2Bf/fLysMCre + BLM treatment groups. Collagen 1a2 mRNA expression
assessed using real-time PCR. Data presented as %-actin. Images are
representative of n ≥ 4 animals from each group. Scale bar, 200 mm.
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Figure 3.2. Myeloid-specific ADORA2B deletion attenuates development of
pulmonary fibrosis after BLM treatment [Adapted from Fig.2 and Fig 3. of (113)].
(A) Masson’s Trichrome collagen staining in whole lung sections with quantitative,
fibrotic histologic scores as given by (B) Ashcroft scores in C57BL/6 and
ADORA2Bf/fLysMCre mice after 33-day i.p. PBS or Bleomycin. (C) Arterial oxygen
saturation in C57BL/6 and ADORA2Bf/fLysMCre mice after PBS or BLM treatment. (AC) Used with permission from Ning-Yuan Chen who performed Trichrome staining and
Harry Karmouty-Quintana who performed pulse oximetry measurements and
assembled data. Results are presented as mean ± SEM, n = 5-7. ***P < 0.001, **0.001
< P < 0.01, and *P < 0.05, comparisons between C57BL/6 + PBS and C57BL/6 + BLM
treatment groups. ###P < 0.001 and #P < 0.05, ANOVA comparisons between C57BL/6
+ BLM and ADORA2Bf/fLysMCre + BLM groups. Images are representative of n ≥ 4
animals from each group. Scale bar: 200μm (4x).
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This reduction in fibrotic endpoints in mice lacking ADORA2B on myeloid cells after
bleomycin treatment were in association with improved arterial oxygen saturation as
compared to bleomycin treatment of C57BL/6 mice (Figure 3.2C). These findings
ultimately indicate myeloid-specific deletion of ADORA2B in a bleomycin-induced
model of lung fibrosis can attenuate pulmonary fibrosis, suggesting a role for
ADORA2B on myeloid cells as a therapeutic target.

BLM exposure of myeloid-specific ADORA2B knockout mice yields reductions
in AAMs and subsequent pro-fibrotic mediator production
To distinguish the changes in macrophage cell type after bleomycin exposure
in ADORA2Bf/fLysMCre mice, lung sections were evaluated for CD206 expression, a
marker of AAMs. Immunostaining for CD206 and semi-quantification of CD206+
macrophages over time showed a decrease in AAMs in bleomycin-treated
ADORA2Bf/fLysMCre mice as compared to C57BL/6 mice after bleomycin exposure
(Figure 3.3A,C). Co-immunofluorescence for pan-macrophage murine marker, F4/80,
and CD206 also revealed a decrease in F4/80+CD206+ macrophages (yellow signal)
in myeloid-specific ADORA2B knockout mice after bleomycin exposure as compared
to C57BL/6 mice (Figure 3.3B). No significant difference was observed however in
iNOS+ macrophages, a marker for the classically-activated macrophage (Figure
3.4A,B). These data reveal the attenuation in fibrosis is due to the absence of
ADORA2B on myeloid cells reducing AAM expression with no effect on CAMs.
Interleukin-6 (IL-6) is a key pro-fibrotic mediator known to be released by
macrophages after activation of ADORA2B(55). IL-6 levels were found to be
significantly increased as early as 14 days after bleomycin exposure and continued to
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increase by day 33 in bronchoalveolar lavage fluid (BALF) from C57BL/6 mice.
However, these levels were significantly reduced in ADORA2Bf/fLysMCre mice after
bleomycin treatment on days 25 and 33 (Figure 3.5A). Immunohistochemistry for IL-6
shows fewer IL-6 positive macrophages on day 33 in ADORA2Bf/fLysMCre mice after
bleomycin treatment as compared to control mice, supporting the observed changes
in IL-6 levels in BALF (Figure 3.5B).

Figure 3.3 Fewer AAMs are observed on day 33 after treatment with BLM or PBS
in myeloid-specific ADORA2B knockout mice [Adapted from Figure 7 and
Supplemental Figure 2 of (113)]. (A) Quantification of CD206+ macrophages identified
morphologically from CD206-stained sections from C57BL/6 + BLM, C57BL/6 + PBS,
and ADORA2Bf/fLysMCre + BLM and ADORA2Bf/fLysMCre + PBS groups at 14, 21, 25,
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and 33 d of treatment. (B) Double immunofluorescence for F/480 (green signals) or
CD206 (red signals) from C57BL/6 mice exposed to BLM (left) and LysM Cre mice
exposed to BLM (right) on day 33. White arrows indicate cells that express both F4/80
and CD206 (cells that co-localize F4/80 and CD206 appear yellow). White asterisks
represent cells that only express F4/80. (C) Immunohistochemistry for CD206 from
formalin-fixed paraffin-embedded (FFPE) lung sections from C57BL/6 + PBS (left)
ADORA2Bf/fLysMCre + PBS (left middle), C57BL/6 + BLM mice (right middle), or
ADORA2Bf/fLysMCre + BLM (right) at day 21 (upper row) or day 33 (bottom row).
Positive staining for CD206 is red/pink; sections were counterstained with Gill’s
hematoxylin. Black arrows point at macrophages positive for CD206.
**0.001

***P

< 0.001 and

< P < 0.01, ANOVA comparisons between C57BL/6 + PBS and C57BL/6 +

BLM treatment groups. #P < 0.01, ANOVA comparisons between C57BL/6 + BLM and
ADORA2Bf/fLysMCre + BLM treatment groups. Images are representative of n ≥ 4
animals from each group. Scale bar, 200 m.
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Figure 3.4. Classically-activated macrophages 33 days after BLM or PBS
exposure

in

myeloid-specific

ADORA2B

knockout

mice.

(A)

Immunohistochemistry for iNOS from formalin-fixed paraffin-embedded (FFPE) lung
sections from C57BL/6 + PBS (left), C57BL/6 + BLM mice (middle), or
ADORA2Bf/fLysMCre + BLM (right) on day 33. Positive staining for iNOS is red/pink;
sections were counterstained with methylgreen. (B) Quantification of iNOS+
macrophages identified morphologically from iNOS-stained sections from C57BL/6 +
BLM, C57BL/6 + PBS, and ADORA2Bf/fLysMCre + BLM and ADORA2Bf/fLysMCre +
PBS groups at 14, 21, 25, and 33 d of treatment. Images are representative of n ≥ 4
animals from each group. Scale bar, 200 m.
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Figure 3.5. IL-6 levels are reduced in ADORA2Bf/fLysMCre mice after BLM
exposure [Adapted from Fig.8 of (113)]. (A) IL-6 levels in BALF from C57BL/6 mice
exposed to BLM or PBS and ADORA2Bf/fLysMCre mice treated with BLM or PBS at 14,
17, 21, 25, and 33 d after treatment. Immunohistochemistry for IL-6 (B) showing
positive staining for IL-6 (red/pink signals) in macrophages (arrowheads) from a
C57BL/6 mouse (left) or an ADORA2Bf/fLysMCre mouse (right) treated with BLM. (A)
Used with permission from Ning-Yuan Chen who performed ELISA for IL-6. Results
are presented as mean ± SEM. *P < 0.05 and **0.001 < P < 0.01, comparisons between
C57BL/6 + PBS and C57BL/6 + BLM treatment groups. #P < 0.05 and

##0.001

<P<

0.01, ANOVA comparisons between C57BL/6 + BLM and ADORA2Bf/fLysMCre + BLM
groups.
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ADORA2B

mediates

hypoxia-induced

macrophage

differentiation

and

production of pro-fibrotic mediators in BMDMs
The data above demonstrate that the absence of ADORA2B on myeloid cells
in bleomycin exposure, reduces AAM expression, and subsequent pro-fibrotic
mediator production. To further clarify the role of ADORA2B in mediating macrophage
differentiation in a robust, in vitro BMDM system, BMDMs were isolated from wild-type
(C57BL/6) and mice with global ADORA2B deletion (ADORA2B-/-) prior to IL-4/IL-13
co-treatment with hypoxia exposure. ADORA2B-/- BMDMs no longer showed robust
increases in Arginase-1 expression or subsequent pro-fibrotic mediator, IL-6,
expression supporting a role for ADORA2B in mediating differentiation of
macrophages into the pro-fibrotic alternatively-activated subtype as described
previously (Figure 3.6A, 3.7C)(48, 108). Similarly, treatment with a pan-adenosine
receptor agonist, 10M NECA, led to significant increases in Arginase-1 expression
and subsequent pro-fibrotic mediators, IL-6 and CXCL1, which were reduced in the
presence of an ADORA2B-specific antagonist, 1M MRS 1754 (Figure 3.6B, 3.7A, B).
However, genetic deletion of ADORA2B in the presence of Th1 cytokines,
lipopolysaccharide (LPS) and interferon-gamma (IFN), showed no significant
difference in classically-activated macrophage (CAM) marker, iNOS, expression
(Figure 3.6C) highlighting the importance and supporting in vivo data above of
ADORA2B in mediating macrophage differentiation into AAMs but not CAMs. These
data reveal the importance of ADORA2B on macrophages in mediating their
differentiation into the pro-fibrotic AAM after hypoxia exposure, and further highlight a
role for ADORA2B antagonists in treatment of pulmonary fibrosis.

74

Figure 3.6. Absence or antagonism of ADORA2B disrupts macrophage
differentiation into AAMs. C57Bl6 and (A,C) ADORA2B-/- BMDMs were polarized
with IL-4 and IL-13 for 72 hours and then incubated in hypoxia (2% O2) for 12 hours
in the presence of (B) 10M NECA, 1M MRS1754, or (C) 100ng/mL
lipopolysaccharide (LPS) with 30ng/mL interferon-gamma (IFN) treatment. (A,B)
Arginase-1 and (C) iNOS, mRNA expression was assessed using real-time PCR. Data
presented as %-actin.

***p

< 0.001,

**0.001

< p < 0.01, and *p < 0.05, ANOVA

comparisons between treatment groups.
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Figure 3.7. Absence or antagonism of ADORA2B disrupts pro-fibrotic mediator
production. (A-C) C57Bl6 and (C) ADORA2B-/- BMDMs were polarized with IL-4 and
IL-13 for 72 hours and then incubated in hypoxia (2% O2) for 12 hours in the presence
of (A-C) 10M NECA or (A,B) 1M MRS1754. (A, C) Interleukin-6 and (B) CXCL1
mRNA expression was assessed using real-time PCR. Data presented as %-actin.
***p

< 0.001 and **0.001 < p < 0.01, ANOVA comparison between IL-4/13 + hypoxia ±

NECA treatment vs NECA ± MRS treatment.
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DISCUSSION
ADORA2B has been shown extensively to mediate pro-fibrotic effects in
pulmonary fibrosis (56). Despite its expression throughout various cell types in the
lung as demonstrated through in-situ hybridization previously, work by Zhou et al.
have illustrated an elevation in ADORA2B-expressing, CD206+ macrophages in IPF
patients and animal models of bleomycin exposure(55, 64). Our studies demonstrate
myeloid-specific ADORA2B deletion followed by bleomycin exposure yields
reductions in pulmonary fibrosis in association with reduced AAM expression and
improved arterial oxygen saturation. A role for ADORA2B in mediating macrophage
differentiation into the pro-fibrotic AAM and subsequent pro-fibrotic mediator
production was illustrated in vitro using ADORA2B genetic deletion and
pharmacologic agonism and antagonism in BMDMs. In accord with previously
published work, ADORA2B deletion in vivo after bleomycin treatment and in vitro
BMDM work revealed ADORA2B does not mediate differentiation of macrophages
into the classically activated pro-inflammatory phenotype. Together, these data
suggest a clinically significant role for myeloid-specific ADORA2B antagonists in
treating patients with IPF.
This work emphasizes the role of ADORA2B on myeloid cells in mediating the
development of pulmonary fibrosis through a mouse model of bleomycin-induced lung
fibrosis and in vitro bone marrow derived macrophage system. Bleomycin treatment
of mice lacking ADORA2B on myeloid cells resulted in decreased pulmonary fibrosis
as evidenced by reductions in fibrotic extracellular matrix proteins including fibronectin
and collagen. Decreases in lung fibrosis were associated with fewer CD206+ AAMs
in late stages of disease as assessed in lung sections along with significant
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improvements in arterial oxygen saturation. These data further support a key role for
AAMs in mediating fibrosis and remodeling in the lung. Although fibrosis was
attenuated with myeloid-specific ADORA2B deletion, it was not completely eradicated
pointing to the importance of other cell-types which may also express ADORA2B in
mediating the development and progression of pulmonary fibrosis. As such, further
work includes delineating the contribution of other cell types in the lung by exposing
conditional knock-out mice for type 1 or type 2 epithelial cells to bleomycin, separately
or in combination with myeloid-specific deletion.
A key finding of this work includes demonstrating the role of ADORA2B on
mediating differentiation of macrophages into the AAM subtype. AAM marker
expression was increased in control BMDMs after hypoxia and Th2 cytokine exposure
but significantly decreased in those BMDMs from ADORA2B-deficient mice.
Pharmacologic antagonism of ADORA2B in BMDMs also led to disruption of AAM
expression as well, in addition to a significant reduction in production of pro-fibrotic
mediators, including IL-6 and CXCL1. Of note however, genetic deletion of ADORA2B
on BMDMs did not inhibit differentiation of macrophages into the classically-activated
macrophage subtype in the presence of Th1 cytokines, IFN and LPS. In fact, Th1
cytokine treatment and hypoxia exposure of BMDMS instead leads to robust increase
in the ADORA2A receptor (Figure 3.8A) while Th2 cytokine treatment contributes to
statistically significant increases in ADORA2B mRNA transcripts as compared to
ADORA2B (Figure 3.8B,C). ADORA3 is known to mediate anti-inflammatory effects
and predominantly expressed in peripheral mononuclear cells and as such, the
increased expression in BMDMs as compared to other adenosine receptors is
expected (Figure 3.8B)(120). In fact, we have previously shown that bleomycin
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exposure in a global ADORA3-/- leads to no significant differences in pulmonary
fibrosis as compared to control ADORA3+/+ mice despite initial increases in
inflammatory markers indicating a role for ADORA3 in regulating anti-inflammatory
features of acute lung injury(69).
In the presence of IL-4 and IL-13 treatment however, both ADORA2B and to a
lesser extent, ADORA2A, mediate differentiation of macrophages to AAMs and
inhibition of these receptors reduce pro-fibrotic mediator production as evidenced by
reductions in Arginase-1 and IL-6 expression with global deletion of ADORA2A or
ADORA2B from BMDMs (Figure 3.9A,B) or pharmacologic antagonism in control
BMDMs (Figure 3.9C,D).
These findings support work by Hasko et al. which illustrate a role for
ADORA2B activation in augmenting the AAM phenotype with production matrix
remodeling and anti-inflammatory mediators in addition to ADORA2A activation as a
means to promote the pro-inflammatory CAM population by suppressing production
of tumor necrosis factor- (TNF), interleukin-12, and nitric oxide(48, 108). Further
work includes validating the observations above in lung macrophages isolated from
bleomycin-treated mice in addition to lung macrophages from patients with and
without IPF.
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Figure 3.8. T-helper cell cytokine treatment and hypoxia exposure alters
adenosine receptor expression. BMDMs were isolated from C57Bl6 mice. On day
7, macrophages were polarized with (A) 100ng/mL LPS and 30ng/mL IFN for 24
hours or (B,C) 10ng/mL IL4 and 10ng/ml IL-13 for 72hrs followed by serum starvation
for 12hrs. PEG-ADA added 30min prior to incubation at 37C in 21% O2 or 2% O2 for
12 hours. Results represent pooled data from biological duplicate experiments.
ADORA1, ADORA2A, ADORA2B, and ADORA3 mRNA expression assessed using
real-time PCR. Data presented as %-actin.
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Figure 3.9. ADORA2A and ADORA2B mediate macrophage differentiation and
pro-fibrotic mediator production. BMDMs from C57BL/6, ADORA2A-/-, and
ADORA2B-/- mice were polarized with 10ng/mL IL4 and 10ng/ml IL-13 for 72hrs
followed by serum starvation for 12hrs. PEG-ADA added 30min prior to treatment
with 10M NECA, 10M ZM 241385, or 1M MRS 1754. PEG-ADA added 30min prior
to incubation at 37C in 21% O2 or 2% O2 for 12 hours. Results represent pooled data
from biological duplicate experiments. Arginase-1 and Interleukin-6 mRNA expression
assessed using real-time PCR. Data presented as %-actin.
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Together, these data demonstrate the role of ADORA2B on myeloid cells in a
bleomycin-induced model of pulmonary fibrosis. They demonstrate that bleomycin
treatment of mice lacking ADORA2B on myeloid cells leads to reductions in AAMs in
association with improved pulmonary function. These results are supported by in vitro
data in BMDMs which reveal the importance of ADORA2B itself in mediating
differentiation of macrophages to the AAM phenotype in the presence of both hypoxia
and a Th2 cytokine rich environment. Chapter 4 assesses the contribution of hypoxia
itself through the hypoxia inducible factor 1A (HIF1A) transcription factor in regulating
ADORA2B expression, macrophage differentiation, and the development of
pulmonary fibrosis utilizing pharmacologic inhibition in an in vivo model along with
BMDMs. Chapter 5 examines the effects of myeloid-specific HIF1A deletion on
pulmonary fibrosis development revealing a role for HIF1A in acute stages of lung
injury.
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CHAPTER FOUR
HIF1A UPREGULATES THE ADORA2B RECEPTOR ON ALTERNATIVELY
ACTIVATED MACROPHAGES AND CONTRIBUTES TO PULMONARY FIBROSIS

INTRODUCTION
Note: This chapter is based upon: Philip K, Mills T, Davies J, Chen NY, KarmoutyQuintana H, Luo F, Molina JG, Amione-Guerra J, Sinha N, Guha A, Eltzschig HK, and
Blackburn MR. HIF1A Up-regulates the ADORA2B receptor on Alternatively Activated
Macrophages and Contributes to Pulmonary Fibrosis. Under Review.

In the preceding chapter, we provide evidence that activation of ADORA2B on
myeloid cells contributes to the development of lung fibrosis by promoting
macrophage differentiation into the pro-fibrotic AAM phenotype in a bleomycininduced model of chronic lung disease(113). In support of these findings, antagonism
of ADORA2B on BMDMs yields reduced AAM expression and subsequent reductions
in pro-fibrotic mediators including interleukin-6 and CXCL1. However, the disease
signals leading to this are unknown, thereby limiting the development of targeting
therapies for IPF.

Hypoxia and Adenosine Signaling
We hypothesized that hypoxia may be the driver of changes in ADORA2B and
AAMs in IPF. Hypoxia, or low oxygen supply, is common in IPF patients and is known
to regulate elements of the adenosine pathway. On history, physical and laboratory
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examination, IPF patients often demonstrate features of chronic hypoxia including
shortness of breath, reduced diffusion capacity of the lung and 6 minute walk distance
(6MWD), and decreased partial pressure of oxygen in arterial blood(2, 81). Increased
immunohistochemical staining for hypoxia inducible factor 1 (HIF1A) on histological
evaluation of lungs from IPF patients also supports the presence of hypoxia(82).
Similarly, animal models of bleomycin-induced chronic pulmonary fibrosis show
decreased arterial oxygen saturation and increased HIF1A in the lungs(83). Hypoxia
stabilizes the transcription factor HIF1A which binds to hypoxia-response elements
within the promoters of target genes involved in the growth of new blood vessels,
programmed cell-death, and glucose metabolism(71). Specifically, HIF1A has been
shown to regulate expression of the ADORA2B receptor, CD73, and equilibrative
nucleotide transporters (ENTs) which allow adenosine transport across the cell
membrane(90, 91). This regulation ultimately leads to elevation of extracellular
adenosine levels and enhancement of ADORA2B signaling.

Experimental Rationale
Although hypoxic conditions are present in IPF and animal models of
pulmonary fibrosis, the role of hypoxia as a direct modulator of macrophage
phenotype remains to be understood. Additionally, factors which regulate adenosine
receptor expression on AAMs and their role in IPF are unknown. An understanding of
AAMs and previous work demonstrating a pro-fibrotic role for ADORA2B receptor led
to hypothesis that both hypoxia through HIF1A and alveolar macrophage
differentiation contribute to the progression of pulmonary fibrosis through upregulation of ADORA2B(55, 56). To address this, I examined lung tissues from
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patients with and without IPF along with luciferase reporter mice during the
progression of pulmonary fibrosis to show activation and stabilization of HIF1A in
alternatively activated macrophages. Next, to understand the role of HIF1A in
regulating ADORA2B expression and the development of pulmonary fibrosis, we
inhibited HIF1A pharmacologically in late stages of disease in a mouse model and
observed attenuated pulmonary fibrosis in association with reductions in ADORA2B
and AAM expression and improved respiratory function. Confirming these in vivo
findings, in vitro studies in BMDMs support a role for ADORA2B in mediating
differentiation of macrophages into AAMs, and further demonstrate that antagonism
or silencing of HIF1Aleads to reductions in ADORA2B expression and ADORA2Bmediated pro-fibrotic mediator production. These studies shed light on the importance
of HIF1A in altering the hypoxic adenosine response in pulmonary fibrosis and
presents a novel means to halting the progression of IPF.

RESULTS
AAMs show HIF1A stabilization in patients with IPF
To characterize ADORA2B expression in IPF, whole lung lysate from patients
with and without IPF was isolated for mRNA and protein analysis. Both ADORA2B
transcript levels and protein expression were increased in patients with IPF as
compared to normal controls along with increased HIF1A protein expression (Figure
4.1A, B). Co-immunofluorescence for the AAM marker, CD206, DAPI nuclear signal,
and HIF1A were carried out in human lung sections from patients with and without IPF
to demonstrate HIF1A stabilization. CD206+ macrophages in patients with IPF show
nuclear localization, or co-localization of DAPI signal and HIF1A, suggesting HIF1A
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stabilization in comparison to normal lungs (Figure 4.1C). These findings support
previous work that patients with IPF show evidence of tissue hypoxemia, leading to
stabilization of HIF1A, and further highlight the importance of alternatively activated
macrophages as the key effector cell type involved in activation and stabilization
HIF1A-mediated pathways.

BLM exposure yields AAMs which exhibit HIF1A stabilization
After demonstrating HIF1A stabilization in AAM’s from patients with IPF, we
next examined HIF1A stabilization in an experimental model of lung fibrosis using
intraperitoneal bleomycin exposure(113). HIF1A luciferase (Hif1::LUC) reporter mice
were injected with bleomycin intra-peritoneally over a four week period to assess
HIF1A stabilization and localization in vivo. Luciferase activity, as measured by
relative Firefly-luciferase to Renilla-luciferase activity, was increased in whole lung
lysate and bronchoalveolar lavage fluid (BALF) from Hif1::LUC reporter mice after
33-day bleomycin-treatment as compared to PBS treatment (Figure 4.2A, B). Cellular
differential of BALF cells demonstrate monocytes and macrophages were the
predominant cell-type which exhibited statistically significant increases in luciferase
activity after bleomycin treatment (Figure 4.2C).
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Figure 4.1 CD206+ macrophages exhibit HIF1A stabilization in idiopathic
pulmonary fibrosis. (A) ADORA2B mRNA expression in whole lung lysate from
patients without (n=5) and with IPF (n=10). ADORA2B expression was assessed
using real-time PCR. Data presented as %18s rRNA. (B) Immunoblot for ADORA2B,
HIF1A, and -actin in whole lung lysate from patients without (n=3) and with IPF (n=9).
(C) Immunofluorescence for HIF1A (red), CD206 (green), and DAPI (blue) from lung
sections of human patients with and without IPF. (White arrow: CD206+ cells that
localize red HIF1A signal in the nucleus with DAPI blue-signal, appear to have purple
nuclei). Results are presented as mean ± SEM. *p < 0.05, Normal healthy lungs vs
IPF patients). Scale bar: 25μm (40x).
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To better understand localization of HIF1A stabilization after bleomycin
exposure, immunofluorescence for Firefly-luciferase, CD206, and DAPI were carried
out in lung sections and bronchoalveolar lavage cells. Bleomycin exposure yields
increased Firefly-luciferase expression, or HIF1A stabilization, in CD206+ AAMs in
whole lung sections and BALF cells as evidenced by greater intensity yellow signal
due to co-localization of red Firefly-luciferase and green CD206 signal in comparison
to Hif1::LUC mice treated with PBS (Figure 4.3A, B). These findings support a role
for hypoxia-dependent HIF1A stabilization in AAMs in mediating fibrosis in a
bleomycin-induced mouse model of pulmonary fibrosis.

Figure 4.2. Macrophages exhibit HIF1A stabilization in pulmonary fibrosis.
Luciferase activity as measured by relative Firefly-luciferase to Renilla-luciferase
activity in whole lung lysate (A) and bronchoalveolar lavage cells (B) of Hif1::LUC
reporter mice after treatment with PBS (n = 2) or BLM (n = 4) for 33 days. (C) Cellular
differential in bronchoalveolar lavage fluid (BALF) from Hif1::LUC reporter mice after
exposure to BLM or PBS for 33 days. Results are presented as mean ± SEM, n = 24. **0.001 < p < 0.01, and *p < 0.05, PBS vs BLM treatment.
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Figure 4.3. CD206+ macrophages exhibit HIF1A stabilization in pulmonary
fibrosis after BLM exposure.

Immunofluorescence for Firefly-luciferase (red),

CD206 (green), and DAPI (blue) in (A) formalin-fixed paraffin-embedded (FFPE) lung
sections and (B) bronchoalveolar lavage cells in Hif1::LUC reporter mice after
treatment with PBS or BLM for 33 days. Scale bar: 25μm (40x).
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A HIF1A inhibitor attenuates pulmonary fibrosis in association with improved
arterial oxygen saturation
Our results suggest bleomycin exposure in a mouse model of lung fibrosis and
in patients with IPF have increased expression and stabilization of the transcription
factor, HIF1Ain AAM’s and may mediate the development of lung fibrosis through
activation of hypoxia-responsive genes. These findings in concert with previous
studies suggesting a role for hypoxia-induced HIF1A in pulmonary fibrosis led us to
investigate whether pharmacologic inhibition of HIF1A would attenuate pulmonary
fibrosis(88, 121). C57BL/6 mice were exposed to intra-peritoneal bleomycin and a
subset were treated with the HIF1A inhibitor, 17-DMAG, beginning on day 20, a time
point where lung fibrosis is already evident(56). 33 days after bleomycin or PBS
exposure, whole lung lysate and lung sections were isolated to assess markers of
fibrosis. HIF1A protein expression in whole lung lysate was reduced in mice treated
with bleomycin and 17-DMAG as compared to bleomycin alone demonstrating the
efficacy of the pharmacologic antagonist in HIF1Aknockdown (Figure 4.4A). Collagen
1A1 transcript levels and Collagen 1 protein expression were increased in C57BL/6
mice after bleomycin treatment as compared to PBS but reduced in the presence of
combined bleomycin and 17-DMAG treatment (Figure 4.4B, C, D). Similarly, another
marker of fibrosis, fibronectin protein expression, was increased in the cohort exposed
to bleomycin as compared to PBS but decreased with bleomycin and 17-DMAG
treatment (Figure 4.4E, F). Immunofluorescence for -smooth muscle actin (SMA)
was next carried out to identify myofibroblasts in lung sections after bleomycin
exposure. Myofibroblasts were increased in fibrotic lesions of the lung in mice after
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Figure 4.4. HIF1A inhibition attenuates fibrotic markers on day 33 after BLM
treatment. Immunoblot for (A) HIF1A, (C) Collagen, and (E) Fibronectin and (A,C,E)
-actin in whole lung lysate from in C57BL/6 mice after 33-day i.p. PBS or Bleomycin
treatment with vehicle or 25mg/kg 17-DMAG. (B) Collagen 1a1 mRNA expression in
whole lung lysate and densitometry analysis from immunoblots for (D) collagen and
(F) fibronectin from C57BL/6 mice after treatment with PBS or BLM ± 17-DMAG. (G)
Immunofluorescence for -smooth muscle actin staining from formalin-fixed paraffinembedded (FFPE) lung sections from C57BL/6 mice after PBS or BLM ± 17-DMAG
treatment. Results are presented as mean ± SEM, n = 5-7. p < 0.001 PBS-Veh vs
Bleomycin-veh, ##0.001 < p < 0.01 and #p < 0.05, C57BL/6 Bleomycin-Veh vs C57BL/6
Bleomycin + 17-DMAG. Collagen 1a1 mRNA expression assessed using real-time
PCR. Data presented as % 18s rRNA. Images are representative of n ≥ 4 animals
from each group. Scale bar: 100μm (10x).
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bleomycin treatment which was attenuated after 17-DMAG treatment of bleomycintreated mice (Figure 4.4G). Masson’s Trichrome collagen staining in whole lung
sections was reduced in mice after bleomycin and 17-DMAG exposure as compared
to bleomycin treatment alone; these histological findings were quantified over multiple
lung sections by Ashcroft scores (Figure 4.5A, B). Collagen levels in bronchoalveolar
lavage fluid as measured by Sircol assay were also reduced in bleomycin-exposed
mice after 17-DMAG treatment in association with improved arterial oxygen saturation
as compared to bleomycin treatment alone (Figure 4.5C, D). These findings reveal
treatment with 17-DMAG, an antagonist to HIF1A, during later stages of disease (day
20 onwards) in a bleomycin-induced model of pulmonary fibrosis can attenuate lung
fibrosis, thereby suggesting a role for HIF1A antagonists in treatment of pulmonary
fibrosis.

HIF1A inhibition attenuates ADORA2B expression and the number of AAMs
Mice treated with intra-peritoneal bleomycin over 33 days showed increased
total, macrophage, lymphocyte, and neutrophil cell counts for which 17-DMAG
treatment led to statistically significant reductions in total and macrophage cell counts;
lymphocytic cells also appeared to be reduced with bleomycin and 17-DMAG
treatment although not statistically significant (Figure 5A, B, C, and D).To elucidate
these changes in macrophage cell count and type, we next evaluated whole lung
lysate and lung sections for CD206 expression, a marker of AAMs. CD206 protein
expression was increased with bleomycin exposure yet reduced with 17-DMAG cotreatment (Figure 4.7A, B).
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Figure 4.5. HIF1A inhibition attenuates development of pulmonary fibrosis after
BLM treatment. (A) Masson’s Trichrome collagen staining in whole lung sections with
quantitative, fibrotic histologic scores as given by (B) Ashcroft scores in C57BL/6 mice
after 33-day i.p. PBS or Bleomycin treatment with vehicle or 25mg/kg 17-DMAG. (C)
Sircol Collagen assay in BALF and (D) Arterial oxygen saturation in C57BL/6 mice
after PBS or BLM treatment ± 17-DMAG. Results are presented as mean ± SEM, n =
5-7.
#p

****p

< 0.001 PBS-Veh vs Bleomycin-veh,

####p

< 0.001,

##0.001

< p < 0.01, and

< 0.05, ANOVA comparison between C57BL/6 Bleomycin-Veh vs C57BL/6

Bleomycin + 17-DMAG. Images are representative of n ≥ 4 animals from each group.
Scale bar: 200μm (4x).
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Figure 4.6. Cellular infiltration after 17-DMAG treatment in a BLM-induced
pulmonary fibrosis model. (A) Total cell counts, (B) macrophages, (C) lymphocytes,
and (D) neutrophils present in bronchoalveolar lavage fluid (BALF) from C57BL/6 mice
after 33-day i.p. PBS or Bleomycin treatment with vehicle or 25mg/kg 17-DMAG.
Results are presented as mean ± SEM, n = 5-7.
PBS-Veh vs Bleomycin-veh,

####p

****p

< 0.001 and **0.001 < p < 0.01

< 0.001 C57BL/6 Bleomycin-Veh vs C57BL/6

Bleomycin + 17-DMAG.
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Immunostaining of lung sections for CD206 and semi-quantification of CD206+
macrophages showed increased AAM in bleomycin-treated mice as compared to mice
treated with bleomycin and 17-DMAG (Figure 4.7C, D). Previously, we demonstrated
a role for ADORA2B expression in myeloid-cells mediating pulmonary fibrosis through
up-regulation of pro-fibrotic AAMs and subsequent production of pro-fibrotic mediators
including IL-6(113). To assess the role of HIF1A in mediating ADORA2B expression
and subsequent pulmonary fibrosis, ADORA2B transcripts were measured in whole
lung lysate and BALF cells after bleomycin and 17-DMAG treatment. Results revealed
increases in ADORA2B transcript in whole lung lysate and BALF cells which were
significantly reduced after treatment with 17-DMAG among BALF cells (Figure 4.7E,
F), shown earlier to be predominantly macrophages. These findings demonstrate 17DMAG treatment attenuates AAMs and ADORA2B expression in lungs of mice after
bleomycin exposure.

Inhibition of HIF1A in bone marrow-derived macrophages lowers ADORA2B and
Arginase-1 expression
In vivo inhibition of HIF1A after bleomycin exposure demonstrated reduced
pulmonary fibrosis consistent with evidence of decreased ADORA2B and AAM
expression and improved arterial oxygen saturation. Next, an in-vitro system of bone
marrow derived macrophages (BMDMs) was utilized to understand the role of hypoxia
through HIF1A in regulating ADORA2B expression and macrophage differentiation
into the AAM subtype. BMDMs cultured in the presence of Th2 cytokines, Interleukin4 (IL-4) and Interleukin-13 (IL-13), as previously described, and exposure to hypoxia
(2% O2) for 6 and 12 hours led to robust increases in AAM marker, Arginase-1
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expression, in comparison to BMDMs treated with IL-4 and IL-13 alone (Figure 4.8A,
B).

Figure 4.7. HIF1A inhibition reduces ADORA2B expression in BALF cells and
subsequent markers of AAMs. (A) Immunoblot for AAM marker, CD206, and β-actin
in whole lung lysate from C57BL/6 mice after 33-day i.p. PBS or BLM treatment with
vehicle or 25mg/kg 17-DMAG. (B) Densitometry analysis for CD206 immunoblot in
C57BL/6 mice after BLM 33 day treatment with 17-DMAG. (C) Immunohistochemistry
for CD206 in FFPE lung sections from C57BL/6 mice after PBS or BLM treatment with
or without 17-DMAG. Positive staining for CD206 is red/pink; sections were
counterstained with Gill’s hematoxylin. Black arrows represent macrophages positive
for CD206. Scale bar: 200 m (40x). (D) Quantification of CD206+ macrophages
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identified morphologically from CD206-stained lung sections from C57BL/6 mice with
PBS or BLM ± 17-DMAG treatment. (E) ADORA2B mRNA expression in whole lung
lysate and (F) BALF cells. ADORA2B (D) expression assessed using real-time PCR.
Data presented as %18s rRNA. (*p≤0.05 PBS-Veh vs Bleomycin-veh, #p≤0.05
C57BL/6 Bleomycin-Veh vs C57BL/6 Bleomycin + 17-DMAG).
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Figure 4.8. Hypoxia exposure yields robust increases in AAMs and regulates
ADORA2B and AAM marker expression in vitro through HIF1A. Bone marrow
derived macrophages from C57Bl6 mice were treated with 10ng/mL IL-4 and 10ng/mL
IL-13 for 72 hours and then incubated in 2% O2 hypoxia for 6 (A) or 12 (A-I) hours in
the presence of (D,E) 100M CoCl2 or 3M 17-DMAG, and (F-H) control siRNA and
siRNA against HIF1A. Immunoblot for HIF1A (E, F), (F) AAM marker, CD206,
ADORA2B, and -actin after (E) CoCl2 or 17-DMAG and (F) control siRNA and siRNA
against HIF1A in BMDMs after 72 hour Th2 cytokine and 12 hour hypoxia treatment .
Arginase-1 (A,B,G) and ADORA2B (C, D,H) expression was assessed using real-time
PCR. Data presented as %-actin.
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Similarly, ADORA2B expression was robustly increased in the presence of
combined IL-4/IL-13 and hypoxia treatment as compared to either IL-4/IL-13 or
hypoxia exposure alone (Figure 4.8C). To test the hypothesis that hypoxia through
HIF1A is largely responsible for mediating ADORA2B expression on Th2-treated
BMDMs, a HIF1A stabilizer, CoCl2, was used in addition to 17-DMAG. Treatment with
CoCl2 led to increased ADORA2B expression which was reversed in the presence of
17-DMAG in association with reductions in HIF1A protein expression (Figure 4.8D, E).
Signal Transduction and Activator of Transcription-6 (STAT-6) is known to be
the predominant signaling pathway through which IL-4 and IL-13 activate
differentiation of macrophages into AAMs (97, 99, 100, 122). To understand the role
for STAT-6 as a regulator of ADORA2B expression on AAMs in culture, BMDMs were
exposed to IL-4/IL-13 and hypoxia in the presence of a STAT-6 inhibitor, AS 1517499
(100nM)(101). STAT-6 inhibition of Arginase-1 expressing BMDMs led to no
significant difference in ADORA2B expression (Figure 4.9A,B).

Figure 4.9. ADORA2B expression on AAMs is STAT6-independent. Bone marrow
derived macrophages from C57Bl6 mice were treated with 10ng/mL IL-4 and 10ng/mL
IL-13 for 72 hours and then incubated in 2% O 2 hypoxia for 12 hours in the presence
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of 200nm AS1517599, a STAT-6 inhibitor. Arginase-1 (A) and ADORA2B (B)
expression was assessed using real-time PCR. Data presented as %-actin.
Confirming the results of HIF1A stabilization and inhibition from above with
CoCl2 and 17-DMAG, genetic knockdown of HIF1Athrough siRNA silencing in IL-4/IL13-treated BMDMs exposed to hypoxia led to reduced HIF1A protein expression and
subsequent ADORA2B mRNA and protein expression in conjunction with reduced
AAMs, as evidenced by decreased CD206 protein and Arginase-1 mRNA expression
(Figure 4.8G, H, and I). Together, these data highlight the role of hypoxia through
HIF1A as the predominant driver of ADORA2B expression on Arginase-1 expressing
BMDMs.

HIF1A antagonism in lung macrophages after bleomycin exposure reduces
ADORA2B and pro-fibrotic mediator expression
To validate the findings above in macrophages after bleomycin-exposure, lung
macrophages were isolated from whole lung after intra-peritoneal bleomycin treatment
and treated with CoCl2 and 17-DMAG. Treatment with HIF1A stabilizer, CoCl2, led to
increases in ADORA2B, IL-6, and CXCL1 expression which were reduced in the
presence of the HIF1A inhibitor, 17-DMAG (Figure 4.10A, B, and C). These data
suggest a role for antagonism of HIF1A in treatment of pulmonary fibrosis by
mediating reductions in ADORA2B expression on AAMs, differentiation of
macrophages further into AAMs, and subsequent pro-fibrotic mediator production.
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Figure 4.10. Antagonism of HIF1A reduces ADORA2B expression and
subsequent pro-fibrotic mediator production in lung macrophages after BLM
treatment. Macrophages were isolated from whole lung lysate of C57BL/6 mice after
i.p. bleomycin treatment for 33 days. Isolated macrophages were then treated with
100M CoCl2 or 3M 17-DMAG for 12 hours. (A) ADORA2B, (B) Interleukin-6, and
(C) CXCL1 mRNA expression was assessed using real-time PCR. Results are
presented as mean ± SEM, n = 2-4. Data presented as %-actin. *p < 0.05 CoCl2
treatment vs no CoCl2, ## 0.001 < p < 0.01 and #p < 0.05 CoCl2 vs CoCl2 + 17-DMAG.

DISCUSSION
Previous work has demonstrated a role for ADORA2B-mediated pro-fibrotic
effects in pulmonary fibrosis(56). Although ADORA2B is expressed throughout the
lung, Zhou et al. demonstrated that ADORA2B-expressing, CD206+ macrophages, a
marker for AAMs, was elevated in patients with IPF and animals models of bleomycininduced chronic lung disease(55). AAM’s have been implicated in many diseases as
a key effector cell type involved in remodeling including asthma and systemic
scleroderma(103, 123). Although, it is known that patients with IPF demonstrate
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clinical features of hypoxia and hypoxemia, the role for hypoxia as a modulator of
adenosine signaling and macrophage differentiation in pulmonary fibrosis remains
unknown. Our studies demonstrated the transcription factor HIF1A as a key hypoxiadependent mediator which is stabilized in IPF patients and mice after bleomycin
exposure. We illustrated a role for HIF1Ain mediating ADORA2B expression and
subsequent AAM differentiation and pro-fibrotic mediator production. Inhibition of
HIF1A in vivo attenuated pulmonary fibrosis in association with reduced ADORA2B
and AAM expression in association with improved arterial oxygen saturation. These
findings were validated in lung macrophages from bleomycin-exposed mice and a
robust in vitro bone marrow-derived macrophage system illustrating the involvement
of hypoxia through HIF1A being a key regulator of ADORA2B expression on
macrophages, their differentiation into the pro-fibrotic AAM subtype, and production
of pro-fibrotic mediators including IL-6 and CXCL1. Our data suggest a clinically
significant use for HIF1A antagonists in targeting the hypoxic adenosine response as
a treatment for patients with IPF.
Hypoxia is known to regulate elements of the adenosine signaling pathway
including down-regulation of CD73 and ENTs leading to increase concentrations of
adenosine in the extracellular space(90, 91). The presence of a hypoxia response
element (HRE) on the promoter of ADORA2B supports the notion that hypoxia through
HIF1A will lead to up-regulation of ADORA2B as described previously(88, 90). HIF1A
transcript and protein expression have been found to be elevated in patients with IPF
and mouse models of bleomycin-induced lung fibrosis(82, 83). A key finding of this
work however emphasizes the nuclear localization and stabilization of HIF1A
specifically in CD206+ macrophages for the first time in patients with IPF and a mouse
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model after bleomycin exposure. These data further support a key role for AAM’s as
a cell type mediating release of pro-fibrotic mediators including IL-6, which further
increase extracellular matrix production and the fibrotic phenotype through IL-6
mediated trans-signaling on fibroblasts in the lung(124). Further studies in
macrophages from bronchoalveolar lavage fluid from patients with and without IPF is
needed to support whole lung findings of HIF1A stabilization on histology. Results
from bleomycin treatment of Hif1::LUC reporter mice support the importance of other
cell-types in stabilization of HIF1A including hypoxia-mediated induction of
deoxycytidine kinase which has been implicated in alveolar epithelial cell
proliferation(84). Further work is needed to delineate the contribution and interplay of
these various cell types in the development and progression of pulmonary fibrosis.
A major finding of this work was the demonstration of a role for HIF1A inhibition
in attenuating pulmonary fibrosis in mice after bleomycin exposure. We previously
showed a role for the presence of ADORA2B on myeloid cells in mediating the
development of pulmonary fibrosis through regulation of AAMs(113). This finding led
us to investigate the hypoxia pathways upstream of ADORA2B which may be involved
and their role in regulating ADORA2B expression and macrophage differentiation. We
showed that treatment with a HIF1A antagonist, 17-DMAG, decreases pulmonary
fibrosis as evident by reductions in key extracellular matrix proteins including collagen
I and fibronectin. This reduction in fibrosis was associated with improvements in
arterial oxygen saturation and significant reductions in ADORA2B transcript levels in
bronchoalveolar lavage cells, known to be comprised significantly of macrophages.
To further elucidate the role of HIF1A-mediated ADORA2B expression on
macrophages, we assessed expression of an AAM marker, CD206, and found
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significant reductions in CD206+ macrophages after 17-DMAG treatment in whole
lung lysate and histology sections. These findings suggest a critical role for
antagonizing hypoxia-dependent HIF1A stabilization through treatment with an
antagonist in late stages of disease as a potential therapeutic for patients with IPF.
These studies are limited however in that 17-DMAG was delivered systemically
through intraperitoneal injection versus localized delivery to the lung; however,
western blot analysis of HIF1A in whole lung lysate suggest that despite systemic
delivery of the drug, we were still able to achieve significant decreases in HIF1A
expression. Recent work suggesting a protective role for HIF1A in epithelial cells in
acute lung injury could lead to further experiments investigating the role of HIF1A
antagonism or genetic knockdown in early stages of disease as well(89).
Patients with IPF are known to have a Th2 cytokine rich environment as evident
through increased presence of IL-4 and IL-13 in bronchoalveolar lavage fluid from
patient samples and immunohistochemical staining(125-128). Although patients with
IPF are known to be hypoxic, the contribution of hypoxia to Th2 cytokine treatment on
ADORA2B expression on macrophages and subsequent differentiation and profibrotic mediator production is unknown. To address this knowledge gap, bone marrow
derived macrophages were utilized and we observed a robust increase in ADORA2B
expression after hypoxia and Th2 cytokine treatment; however, we further illustrated
that this increase in ADORA2B expression on macrophages is predominantly
mediated by hypoxia through HIF1A as demonstrated by reductions in ADORA2B
expression with addition of HIF1A antagonist treatment to hypoxia as compared to no
significant change in ADORA2B expression with addition of a STAT-6 inhibitor. Similar
results were observed with reductions in ADORA2B expression, Arginase-1 and
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CD206 expression with genetic silencing of HIF1A. These findings were validated in
another macrophage system, lung macrophages isolated from mice after bleomycin
treatment, wherein co-treatment of 17-DMAG with CoCl2, HIF1A stabilizer, led to
reductions in ADORA2B, IL-6, and CXCL1. These data support another major finding
from this study that hypoxia through HIF1A regulates ADORA2B expression on
macrophages, differentiation of macrophages into AAMs, along with pro-fibrotic
mediator production. Antagonism of HIF1A in BMDMs led to decreases in pro-fibrotic
mediator production revealing new targets for halting the progression of pulmonary
fibrosis in patients with IPF. Future work will include elucidating the impact of hypoxiaindependent pathways, whether stretch-induced or metabolite-mediated, on upstream
HIF1A stabilization. The HIF2A subunit has also gained attention as it has been shown
to play a role in the development of pulmonary hypertension and fibrosis in geneticallymodified mice(121). Recent work by Cowburn et al. suggest the development of
pulmonary hypertension may be due to hypoxia-induced HIF2A stabilization which
increases arginase expression thereby disrupting protective effects of nitric oxide on
the pulmonary vasculature(129). As such, further work may include investigating the
contribution of HIF2A in the development of pulmonary fibrosis and associated
pulmonary hypertension after bleomycin exposure. It may also be insightful to
elucidate the possibly differing role of adenosine receptor expression, role of HIF1A
stabilization, and differentiation on alveolar, interstitial, or recruited macrophages in
pulmonary fibrosis alongside validation in macrophages isolated from patients with
and without IPF.
In Chapter 3 of the dissertation, we reveal a role for the presence of ADORA2B
on myeloid cells in promoting their differentiation into the AAM subtype, production of
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pro-fibrotic mediators, and ultimately, the development of pulmonary fibrosis after
bleomycin exposure. The contribution of hypoxia as a regulator of ADORA2B
expression on AAMs and development of pulmonary fibrosis is explored in this
chapter. I found that antagonism or genetic silencing of HIF1A can attenuate profibrotic mediator production and pulmonary fibrosis in bone marrow derived
macrophages (BMDMs) and in vivo models of bleomycin-induced pulmonary fibrosis.
In the following chapter, I will examine the effect of myeloid-specific HIF1A deletion
on the development and progression of pulmonary fibrosis and a pivotal role which
HIF1A plays in acute stages of disease.
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CHAPTER FIVE
MYELOID-SPECIFIC HIF1A DELETION EXACERBATES ACUTE LUNG INJURY
CONTRIBUTING TO PULMONARY FIBROSIS

INTRODUCTION
Note: This chapter is based upon: Philip K, Mills T, Davies J, Chen NY, KarmoutyQuintana H, Hernandez A, Luo F, Molina JG, Eltzschig HK, and Blackburn MR.
Myeloid-specific HIF1A deletion exacerbates acute lung injury. In Preparation.

In the previous chapter, I demonstrate a role for ADORA2B on myeloid cells in
mediating macrophage differentiation and subsequent pro-fibrotic mediator production
in an in vivo bleomycin-induced model of lung fibrosis and bone marrow derived
macrophages(113). Chapter 4 then explores how hypoxia through HIF1A acts as a
regulator of ADORA2B expression on AAMs and HIF1A inhibition in late stages of
disease can be used to attenuate the development of pulmonary fibrosis in an in vivo
mouse model. Additionally, bone marrow derived macrophages were used to decipher
between the roles of Th2 cytokine signaling through STAT-6 and hypoxia through
HIF1A in culture in mediating ADORA2B expression, AAM differentiation, and
subsequent interleukin-6 production. Although these studies provide evidence for a
therapeutic role of HIF1A or ADORA2B inhibition in the development and progression
of pulmonary fibrosis, the role of HIF1A on myeloid cells in altering adenosine
signaling and the inflammatory mileau in early stages of lung injury remains to be
understood and will be discussed in this chapter.
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HIF1A in Lung Disease
Numerous pulmonary diseases are known to result in hypoxia and more
attention has been drawn to the interplay between hypoxia and inflammation(51).
Systemic or organ-specific hypoxia has been shown to promote an inflammatory
response including immunocyte recruitment, increased endothelial cell permeability
and resulting vascular leakage, and the activation of proinflammatory signaling
pathways, cytokines, and chemokines(130). Inflammation itself, including increases
in mediators such as nitric oxide, can contribute to the development of hypoxia and
subsequent HIF1A expression, ultimately disrupting epithelial cell wound repair(72,
131). Although multiple mechanisms exist to activate HIF, hypoxia-dependent PHD
inhibition and subsequent HIF1A stabilization is the focus of this chapter as HIF1A is
known to be stabilized in patients with IPF, mouse models of bleomycin-induced lung
injury, and we have demonstrated in the preceding chapters its activation in lung
macrophages from patients with IPF and animal models of disease (75, 82, 83)
Recent work by Eckle et al. observed exacerbations in pulmonary edema and
inflammation after alveolar-epithelial cell specific HIF1A knockout mice were exposed
to ventilator-induced lung injury suggesting a protective, anti-inflammatory role for
HIF1A (89). They later showed that stabilization of HIF1A in this cyclic mechanicalstretch induced model of lung injury lead to upregulation of ADORA2B in epithelial
cells and subsequent anti-inflammatory effects in agreement with previous work from
our laboratory revealing an anti-inflammatory, protective role for ADORA2B itself in
acute lung injury(56, 88). In support of a pro-fibrotic role for HIF1A in this same cell
type, alveolar epithelial cells, our lab has shown that hypoxia-mediated HIF1A
stabilization can also induce deoxycytidine kinase expression in alveolar epithelial
108

cells contributing to their proliferation and the development of lung fibrosis in a model
of bleomycin-induced chronic lung disease (84). Myeloid-specific HIF1A knockout
mice showed decreased airway hyperresponsiveness and recruitment of asthmatic
inflammatory mediators, eosinophils, when exposed to ovalbumin supporting
however a protective anti-inflammatory role of HIF1A in acute lung injury in another
cell type (132).

Together these studies demonstrate a tissue-protective, anti-

inflammatory role for HIF1A in acute stages of lung injury in differing cell types.
However, the role of HIF1A in myeloid cells in acute stages of a bleomycin-induced
lung injury model and its subsequent effects on late stages of disease remain to be
understood and will be the focus of this chapter.

Experimental Rationale
We have previously demonstrated differing roles for ADORA2B depending on the
stage of disease. In an intra-tracheal model of bleomycin-induced acute lung injury,
ADORA2B-/- mice are found to exhibit increases in pulmonary edema and acute
inflammatory markers revealing a protective and anti-inflammatory role for ADORA2B
in acute lung injury(54, 56). ADORA2B-/- mice however exposed to an intra-peritoneal
model of bleomycin-induced chronic lung disease show reductions in fibrotic markers
such as collagen and fibronectin, attenuated fibrosis and profibrotic mediators
including

macrophages

expressing

interleukin-6,

and

clinical

improvement

demonstrating a detrimental role for ADORA2B in chronic lung disease(56).
The previous chapter directly illustrates how antagonism of HIF1A can lead to
reductions in ADORA2B, disrupted macrophage differentiation into the profibrotic
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AAM subtype, and subsequently attenuate lung fibrosis; ultimately, revealing a novel
therapeutic target for patients with IPF. To investigate the impact of HIF1A on lung
disease in acute stages of injury, a myeloid-specific HIF1A knockout mice was
generated and exposed to saline or bleomycin over the 33 day time course. Samples
were collected at initial stages of injury, day 3, 7 and 14, in addition to late stages of
disease, 21 and 33 to evaluate the role HIF1A may play as a regulator in mediating
the differing roles of ADORA2B on myeloid cells in acute versus chronic lung injury.

RESULTS
Myeloid-specific

HIF1A

deletion

alters

temporal

changes

in

cellular

inflammation and increases neutrophil infiltration after BLM exposure
HIF1Af/fLysMCre and LysMCre mice were treated with intra-peritoneal bleomycin
over 33 days, sacrificed, and samples collected at varying time points. Overall, mice
lacking ADORA2B on myeloid cells showed similar trends but still a significant
reduction in total cell count in bronchoalveolar lavage fluid when compared to control
mice after bleomycin treatment by day 20 (Figure 5.1A). Upon closer evaluation of the
cellular differential in BALF, it is evident that HIF1Af/fLysMCre treated with bleomycin
show significant increases in acute inflammatory mediators, including neutrophils by
day 7 and lymphocytes by day 14 as compared to LysMCre mice after bleomycin
exposure (Figure 5.1B,C, 5.2A). Macrophage cell counts followed an increase by day
14 and 20 after bleomycin treatment for both HIF1Af/fLysMCre and LysMCre mice
although they were significantly reduced in mice lacking ADORA2B on myeloid cells
(Figure 5.1D). To further distinguish these changes in neutrophil cell count by day 7,
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lung sections were stained for Ly.6b expression, a surface marker found on murine
neutrophils (Figure 5.2B) (133). Semi-quantification of Ly.6b positive cells shows
increased neutrophils in bleomycin-treated HIF1Af/fLysMCre mice as compared to
LysMCre mice after bleomycin exposure (Figure 5.2C).

Figure 5.1. Temporal changes in cellular infiltration after BLM exposure. (A) Total
cell counts, (B) neutrophils, (C) lymphocytes, and (D) macrophages present in
bronchoalveolar lavage fluid (BALF) from HIF1Af/fLysMCre and LysMCre mice after i.p.
PBS or Bleomycin treatment for 3, 7, 14, 20, or 33 days. Results are presented as
mean ± SEM, n = 5-12. ****p < 0.001, **0.001 < p < 0.01, *p < 0.05, ANOVA comparison
between LysMCre + PBS and LysMCre + Bleomycin.

####p

< 0.001,

##0.001

< p < 0.01,

and #p < 0.05, ANOVA comparison between LysMCre + Bleomycin and HIF1Af/fLysMCre
+ Bleomycin.
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Figure 5.2 BLM exposure in myeloid-specific HIF1A knockout mice increases
early neutrophil infiltration. (A) Neutrophils cell counts in bronchoalveolar lavage
fluid (BALF), (B) Immunohistochemistry for Ly.6b in FFPE lung sections, and (C) semiquanitification of Ly.6b positive cells identified morphologically in stained sections from
HIF1Af/fLysMCre and LysMCre mice after i.p. PBS or Bleomycin treatment for 7 days.
Positive staining for Ly.6b is brown; sections counterstained with methylgreen. Black
arrows represent Ly.6b positive cells, or neutrophils. Results are presented as mean
± SEM, n = 5-12. *p < 0.05, ANOVA comparison between LysMCre + PBS and LysMCre
+ Bleomycin. #p < 0.05, ANOVA comparison between LysMCre + Bleomycin and
HIF1Af/fLysMCre + Bleomycin. Images are representative of n ≥ 4 animals from each
group.
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HIF1A deletion on myeloid cells exacerbates acute lung injury after BLM
exposure
Results above suggest bleomycin exposure in mice lacking HIF1A on myeloid
cells lead to alterations in acute inflammatory mediators including neutrophils and
lymphocytes in comparison to control mice after bleomycin treatment. These
observations lead us to further investigate other markers of acute lung injury. Next, to
assess loss of the pulmonary barrier function and the development of pulmonary
edema, we evaluated albumin levels in the BALF on day 7 and found significant
increases in HIF1Af/fLysMCre mice after bleomycin exposure as compared to control
mice with bleomycin treatment (Figure 5.3A). To further evaluate chemokines involved
in neutrophil recruitment in the setting of acute lung injury, we evaluated mRNA levels
of monocyte chemotactic peptide-1 (MCP-1) and found increases in control
bleomycin-treated LysMCre mice which were robustly increased after bleomycin
treatment in mice lacking HIF1A on myeloid cells (Figure 5.3B) (31, 37, 38). Similarly,
another indicator of acute lung injury, Myeloperoxidase (MPO), a major component of
neutrophil cytoplasmic granules revealing neutrophil presence, was found to be
significantly increased in BALF on day 7 after bleomycin exposure in HIF1A f/fLysMCre
mice (Figure 5.3C)(134). These findings reveal myeloid-specific HIF1A deletion
followed by acute lung injury through bleomycin exposure will not only increase
neutrophil count, but contribute to worsening pulmonary edema, greater neutrophil
recruitment, and ultimately, increased inflammation, thereby suggesting a protective
role for HIF1A in acute lung injury.

113

Figure 5.3 Deletion of HIF1A on myeloid cells exacerbates ALI markers in BLMinduced lung fibrosis. (A) Albumin concentration in bronchoalveolar lavage fluid, (B)
MCP-1 mRNA expression in whole lung lysate, and (C) myeloperoxidase activity in
bronchoalveolar lavage fluid after bleomycin exposure at day 7 in HIF1Af/fLysMCre and
LysMCre mice. Results are presented as mean ± SEM, n = 5-12.

###p

< 0.001, #p <

0.05, ANOVA comparison between LysMCre + Bleomycin and HIF1Af/fLysMCre +
Bleomycin. MCP-1 mRNA expression assessed using real-time PCR. Data presented
as % 18s rRNA.

HIF1A deletion on myeloid cells increases pulmonary fibrosis in association
with worsened arterial oxygen saturation
Thus far, data reveal an anti-inflammatory role for HIF1A on myeloid cells in
acute stages of bleomycin exposure as evidenced by increases in acute inflammatory
mediators, neutrophil recruitment, count, MPO, and loss of barrier function in
bleomycin-treated myeloid specific HIF1 knockout mice. This worsening of acute lung
injury due to loss of HIF1A on myeloid cells led us to investigate whether pulmonary
fibrosis would also be exacerbated as has been shown previously(135).

LysMCre

control mice and HIF1Af/fLysMCre mice were treated with bleomycin intraperitoneally
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over 33 days. Assessing fibrotic markers in whole lung lysate on day 33 reveal
increased fibronectin protein expression and collagen 1a1 transcript levels in mice
lacking ADORA2B on myeloid cells as compared to bleomycin treatment of control
mice alone (Figure 5.4 A,B). Immunofluorescence for -smooth muscle actin (SMA),
a marker of myofibroblasts in lung sections, revealed increased staining after
bleomycin treatment of control mice as compared to saline which was further
increased in HIF1Af/fLysMCre mice after bleomycin treatment in association with
reductions in arterial oxygen saturation (Figure 5.4C,D). Masson’s Trichrome collagen
staining in whole lung sections was increased in LysMCre mice after bleomycin
exposure by day 14 and continued to increase by day 21 and 33 (Figure 5.5A).
HIF1Af/fLysMCre mice exposed to bleomycin shows similar increase in collagen
staining by day 14 but demonstrated statistically significant increases in collagen
staining as quantified by Ashcroft histological score by day 33 (Figure 5.5 A,B).
Together, these data reveal myeloid specific HIF1A deletion in a bleomycin-induced
model of lung fibrosis will worsen lung fibrosis, as a result of the loss of the protective
anti-inflammatory effects of HIF1A in acute stages of disease.
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Figure 5.4 Fibrotic markers are increased on day 33 after BLM exposure in mice
lacking HIF1A on myeloid cells. Immunoblot for (A) Fibronectin and (B) Collagen
1a1 mRNA expression in whole lung lysate from HIF1Af/fLysMCre and LysMCre mice
after i.p. PBS or Bleomycin exposure on day 33. (C) Immunofluorescence for alphasmooth muscle actin staining from formalin-fixed paraffin-embedded (FFPE) lung
sections and (D) Arterial oxygen saturation in HIF1Af/fLysMCre and LysMCre mice after
33 days of bleomycin treatment. Images are representative of n ≥ 4 animals from each
group. Scale bar: 100μm (10x).
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Figure 5.5 Myeloid HIF1A deletion exacerbates the development of pulmonary
fibrosis after BLM treatment. (A) Masson’s Trichrome collagen staining in whole
lung sections with quantitative, fibrotic histologic scores as given by (B) Ashcroft
scores in HIF1Af/fLysMCre and LysMCre mice after i.p. PBS or Bleomycin exposure on
day 14, 20, and 33. Results are presented as mean ± SEM, n = 5-7.

PBS vs LysMCre + Bleomycin and

****

p < 0.001 LysMCre +

p < 0.001, ANOVA comparison between LysMCre +

####

Bleomycin and HIF1Af/fLysMCre + Bleomycin.
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Myeloid-specific HIF1A deletion attenuates ADORA2B and AAM expression
after BLM exposure
HIF1Af/fLysMCre after bleomycin treatment showed increases in macrophage
cell count as observed in bleomycin-treated LysMCre however, they were significantly
reduced compared to treated control mice at day 14 and 21 (Figure 5.1D). To decipher
these changes in macrophage cell count, whole lung lysate was evaluated for markers
of AAMs. CD206 protein expression was increased with bleomycin exposure in control
LysMCre mice as compared to PBS treatment but reduced in those bleomycin-treated
mice lacking ADORA2B on myeloid cells (Figure 5.6A). In accord with this, transcript
levels in lung lysate of another AAM marker, Arginase-1, were increased with
bleomycin exposure and reduced in myeloid-specific HIF1A knockout mouse (Figure
5.6B). In Chapter 3, I demonstrated that activation of ADORA2B on myeloid cells upregulates pro-fibrotic AAMs, profibrotic mediators, and contributes to the development
of pulmonary fibrosis(113). In chapter 4, HIF1A was found to mediate ADORA2B
expression on BMDMS and in vivo attenuating lung fibrosis. In agreement with these
findings, ADORA2B transcript levels were increased after bleomycin exposure in
control mice yet reduced in bleomycin-treated mice lacking HIF1A on myeloid cells.
Together, these results demonstrate myeloid-specific HIF1A deletion reduces AAM
and ADORA2B expression after bleomycin exposure.
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Figure 5.6. Conditional myeloid-specific HIF1A deletion yields decreased
ADORA2B and AAM expression after BLM-induced pulmonary fibrosis. (A)
Immunoblot for CD206 and -actin, (B) Arginase-1, and ADORA2B transcript levels
(C) in whole lung lysate from HIF1Af/fLysMCre and LysMCre mice exposed to bleomycin
or PBS 33 days after treatment. Arginase-1 and ADORA2B expression was assessed
using real-time PCR. Data presented as %18s rRNA.

HIF1A deletion in myeloid cells in bone marrow-derived macrophages lowers
Arginase-1 and production of pro-fibrotic mediators
In vivo bleomycin exposure in myeloid-specific HIF1A conditional knockout
mice resulted in exacerbated pulmonary inflammation and subseqent increases in
fibrosis despite reductions in ADORA2B and AAM expression. To confirm the role of
hypoxia through HIF1A in regulating macrophage differentiation observed in chapter
4, bone marrow-derived macrophages from HIF1Af/fLysMCre and LysMCre mice were
cultured in the presence of IL-4 and IL-13 and exposed to hypoxia for 12 hours.
Treatment of hypoxia and Th2-cytokine treated LysMCre BMDMs with NECA, a panadenosine receptor agonist, resulted in increases in Arginase-1, Interleukin-6, and
CXCL1 transcript levels which were significantly reduced in BMDMS lacking HIF1A
(Figure 5.7A,B,C). This suggests HIF1A on myeloid cells is needed for ADORA2B119

mediated stimulation of macrophage differentiation into AAMs and profibrotic mediator
production.

Figure 5.7. AAM and pro-fibrotic mediator expression is reduced after
adenosine receptor activation in BMDMS lacking HIF1A. HIF1Af/fLysMCre and
LysMCre BMDMs were treated with IL-4 and IL-13 for 72 hours, then incubated in
hypoxia (2% O2) for 12 hours in the presence of 10M NECA. (A) Arginase-1, (B)
Interleukin-6, and (C) CXCL1 mRNA expression was assessed using real-time PCR.
Data presented as %-actin.

DISCUSSION
HIF1A has received recent attention as a transcription factor which can play a
protective role in various types of acute lung injury including normoxic ventilatorinduced lung injury and ovalbumin challenge models of airway hyperresponsiveness
and asthma(89, 132). These findings however were specific to other cell types in the
lung including alveolar epithelial cells and eosinophils. In Chapter 4, we demonstrated
stabilization of HIF1A in macrophages from IPF patients and bleomycin-induced
models of lung injury; in this chapter however, I utilized a myeloid-specific HIF1A
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knockout mice to understand the role HIF1A plays in acute and chronic stages of a
bleomycin-induced model of lung injury.
The results above demonstrate myeloid-specific HIF1A deletion followed by
bleomycin exposure leads to worsening of pulmonary inflammation in acute stages
and subsequent pulmonary fibrosis in association with reductions in arterial oxygen
saturation. In accord with results of the previous chapter, a role for HIF1A in regulating
ADORA2B expression, macrophage differentiation, and subsequent profibrotic
mediator production was illustrated in chronic stages of a bleomycin-induced lung
disease and BMDMs from conditionally modified mice lacking HIF1A on myeloid cells.
Moreover, these studies support a role for myeloid-specific HIF1A agonists or
stabilizers in treating patients with acute lung injury or myeloid-specific HIF1A
antagonists or inhibitors in patients with chronic lung diseases such as IPF.
A mouse model of bleomycin-induced lung injury in acute stages of disease
reveals a protective role for HIF1A on myeloid cells in reducing inflammation. Mice
lacking HIF1A in myeloid cells showed exacerbations of acute lung injury including
increased pulmonary edema, acute inflammatory markers, chemokines, and
neutrophil recruitment. These data are novel in that they are the first to suggest HIF1A
in AAMs as a key factor in reducing inflammation and protecting pulmonary barrier
function in a bleomycin-induced model of lung injury. Crotty et al. recently showed
inhibition of HIF1A and myeloid-specific HIF1A knockouts exposed to ovalbumin had
reductions in airway hyper-responsiveness and eosinophil recruitment, features of
asthma pathogenesis(132). Supporting a similar anti-inflammatory role, Eckle et al.
demonstrate HIF1A stabilization in normoxia under mechanical stretch and ventilatorinduced acute lung injury leads to decreases in pulmonary edema and inflammation
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associated with maximal carbohydrate metabolism in vivo; these observations were
exacerbated in alveolar-epithelial cell specific HIF1A knockout mice after VILI,
localizing this anti-inflammatory role of HIF1A to alveolar epithelial cells(89). As such,
our findings further support previous work indicating HIF1A plays an anti-inflammatory
role in myeloid cells in acute lung injury, or bleomycin exposure as demonstrated here.
Further work includes investigating the contribution of other cell types which exhibit
HIF1A stabilization in the bleomycin lung injury model. Additionally, evaluating
conditions that promote HIF1A stabilization in normoxic conditions in myeloid cells
may be key to preventing inflammation and subsequent fibrosis development in
patients at risk for the development of IPF or other chronic lung diseases.
This work supports the consistent finding observed in previous chapters that
HIF1A drives ADORA2B expression, macrophage differentiation, and pro-fibrotic
mediator production. Thirty-three day bleomycin exposure in myeloid-specific HIF1A
knockout mice resulted in decreased CD206 protein, Arginase-1, and ADOR2B
transcript levels in whole lung lysate. Given the reductions in ADORA2B as regulated
by HIF1A, one may expect lung fibrosis to be reduced as well based on findings from
the two previous chapters; however, the resultant increase in fibrosis differs from the
previous studies in that lung injury due to bleomycin exposure was exacerbated
acutely secondary to myeloid-specific HIF1A deletion in comparison to myeloidspecific ADORA2B deletion (Chapter 3) or HIF1A inhibition in late stages of disease
(Chapter 4). We have previously observed similar increases in inflammation as
evidenced by lowered adenosine levels and increasing cellular infiltration, proinflammatory mediators including interleukin-1, TNF, which contributed to
increased lung fibrosis after bleomycin treatment of CD73-/- mice(135). CD73 is known
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to have a HRE on its promoter and as such it maybe that myeloid-specific HIF1A
deletion leads to decreased levels of CD73, lowering adenosine levels, and ultimately
exacerbating injury in the acute phase of a bleomycin-induced model of lung
injury(92). TGF is another mediator which was found to be elevated in lung
macrophages after adenosine-dependent lung injury in which increased inflammation
and subsequent fibrosis was observed in ADA-/- mice which improved with
antagonism of ADORA2B (136). These elevations in TGF were also observed in
ADORA2B-/- mice during acute stages of the bleomycin-induced lung injury model
(56). Further work to evaluate the mechanism by which HIF1A deletion on myeloid
cells exacerbates acute lung injury includes assessing adenosine levels in
bronchoalveolar lavage fluid, CD73 and TGF expression in whole lung lysate and
lung sections, in addition to evaluating pro-inflammatory and pro-fibrotic mediators.
Moreover, these data demonstrate an anti-inflammatory role for HIF1A on
myeloid cells in acute lung injury. Mice lacking HIF1A on myeloid cells exhibit
increased inflammation and pulmonary edema which contributes to increases in
fibrotic markers including collagen and fibronectin and the development of fibrosis in
later stages of disease. Chapter 3 and 4 revealed how activation of ADORA2B and
HIF1A stabilization ultimately mediate macrophage differentiation into AAMs and profibrotic mediator production. In agreement, this chapter illustrated a decrease in AAM
and ADORA2B expression in conditional myeloid-specific HIF1A knockouts after
bleomycin exposure and BMDMS after NECA treatment.
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CHAPTER SIX
SUMMARY, FUTURE DIRECTIONS, AND CONCLUSION
SUMMARY
IPF is a common, chronic disease which significantly impacts the quality of life of
millions of individuals worldwide. Median survival after diagnosis is typically 3-5 years
due to the absence of any curative treatment(1, 128, 137). Previously published work
from our lab and others have demonstrated a role for adenosine accumulation and
activation of ADORA2B as a key regulator of fibrosis in vivo and in conjunction with
human samples of IPF, ADORA2B expression and IL-6 production has been localized
to alternatively, activated macrophages as a key effector cell-type in this process(50,
55, 56). The work in this dissertation sought to identify factors which regulated
expression of ADORA2B on macrophages, elucidate the role ADORA2B in
macrophage differentiation and development of fibrosis, and assess the impact of
inhibiting HIF1A in late stages of disease versus myeloid-specifIc HIF1A deletion on
pulmonary fibrosis.
Bleomycin exposure of myeloid-specific ADORA2B knockouts revealed
reductions in markers of fibrosis including collagen, fibronectin, and myofibroblast
expression in association with improvements in arterial oxygen saturation. Upon
further inspection of macrophage cell counts and type, we found that the attenuation
of fibrosis was also associated with reductions in AAMs in whole lung lysate and
sections along with less ADORA2B-mediated pro-fibrotic cytokine IL-6 in BALF and
fewer IL-6 positive macrophages. Antagonism and genetic deletion of ADORA2B
followed by exposure to Th2 cytokines and hypoxia revealed a role for ADORA2B
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itself in mediating macrophage differentiation into AAMs and the production of
profibrotic mediators. These results supported a role for ADORA2B on myeloid cells
in mediating their differentiation into AAMs and promoting production of profibrotic
cytokines and chemokines that lead to the development and progression of pulmonary
fibrosis.
Lung sections from patients with and without IPF along with bleomycin-induced
lung fibrosis in Hif1::LUC reporter mice for the first time demonstrated stabilization
of HIF1A in AAMs. Next, inhibition of HIF1A in late stages of a bleomycin-induced lung
injury model revealed reductions in ADORA2B and AAM expression in association
with attenuation of pulmonary fibrosis. Inhibition and genetic silencing of HIF1A in
BMDMs also showed disruption of HIF1A-mediated ADOR2B expression, subsequent
AAM marker expression including Arginase-1 and CD206. These results were
confirmed in lung macrophages from mice after bleomycin treatment along with
exhibiting reductions in IL-6 and CXCL1.
To further characterize the role of HIF1A in regulating ADORA2B expression
subsequent development of fibrosis, a myeloid-specific HIF1A knockout mouse was
exposed to saline and bleomycin. Results showed exacerbations in inflammatory
parameters in acute stages of disease which lead to exacerbated lung fibrosis in late
stages of disease as well. However, both ADORA2B and AAM expression remained
reduced on day 33 after bleomycin exposure, confirming previous findings that HIF1A
does regulate ADORA2B expression on AAMs. Further work to elucidate the
mechanisms by which HIF1A deletion on myeloid cells contributes to breakdown of
the alveolar-epithelial cell barrier and increased inflammation leading to the
development of fibrosis is needed.
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Figure 6.1. Working model of the hypoxic adenosine response on AAMs in lung
disease. Patients with IPF have increased levels of adenosine and ADORA2Bexpressing AAMs (work done by Yang Zhou, PhD). (A) We demonstrate a role for
ADORA2B on AAMs in contributing to the development of lung fibrosis due to (B)
ADORA2B-mediated increases in macrophage differentiation into AAMs and
subsequent pro-fibrotic mediator production. (C) Hypoxia-induced HIF1A stabilization
in AAMs contributes to increased ADORA2B expression, (B) AAM differentiation, and
development of pulmonary fibrosis which can be reversed with 17-DMAG treatment
(a HIF1A inhibitor). (D) In acute lung injury, myeloid-specific HIF1A plays a tissue
protective and (E) anti-inflammatory role.
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This dissertation address several knowledge gaps with respect to how hypoxia
alters adenosine signaling in lung disease and contributes to the development of
fibrosis. We demonstrate a role for ADORA2B on myeloid cells in contributing to
macrophage differentiation into AAMs, pro-fibrotic mediator production, and the
development of lung fibrosis(113). I later illustrated how hypoxia through HIF1A acts
as a major driver of ADORA2B on macrophages in BMDMs and for the first time,
demonstrated its stabilization in human lung sections from patients affected by IPF in
addition to murine models of bleomycin-induced lung injury. I then illustrated how
inhibition of HIF1A in late stages of disease can attenuate lung fibrosis by reducing
ADORA2B expression, AAM differentiation, and pro-fibrotic mediator production in
vivo with supporting findings in BMDMs through genetic silencing and pharmacologic
antagonism. Lastly, through myeloid-specific HIF1A deletion followed by bleomycin
exposure, an anti-inflammatory role for HIF1A in myeloid cells is revealed in acute
stages of disease.
The findings from this dissertation are significant in that they emphasize the
clinical importance of myeloid-specific ADORA2B antagonism or HIF1A inhibition in
late stages of disease in attenuating the progression of lung fibrosis. These therapies
could significantly prolong the lives of patients living with IPF by reducing symptoms
or acute exacerbations, and ultimately, provide them a better quality of life. HIF1A
stabilization in acute lung injury to reduce inflammation, breakdown of the pulmonary
barrier, and worsened fibrosis in the long-term, also presents a novel therapy for
patients affected by acute lung injury. Before translating to patient care however, the
exact mechanisms behind HIF1A stabilization contributing to decreased inflammation
need to be investigated further.
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FUTURE DIRECTIONS
The work presented in this dissertation contributes to our understanding of how
hypoxia modulates adenosine signaling and macrophage differentiation, contributing
to pulmonary fibrosis. However, there are still many questions which remain to be
answered and findings confirmed to delineate the mechanisms and key players in this
complex disease process.

What role does ADORA2B on myeloid cells contribute to pulmonary fibrosis
development in comparison to other cell-types in the lung?
Deletion of ADORA2B on myeloid cells followed by bleomycin exposure
showed attenuation of fibrosis but not complete abolishment of lung fibrosis. This
suggests that myeloid-specific deletion alone is not enough to halt the progression of
fibrosis and that the presence of ADORA2B on other cell-types may play a role
including type 1 or 2 alveolar epithelial cells. To investigate this, ADORA2Bf/f mice
crossed with mice carrying Cre recombinase under differing tissue-specific promoters,
such as surfactant protein c (SPC) for type 2 epithelial cell-specific deletion or
aquaporin 5 (Aqp5) for type 1 epithelial cell-specific deletion, should be exposed to
bleomycin- induced lung fibrosis to delineate the role ADORA2B may play on these
cell types in contributing to the development and progression of fibrosis(138).
Differing roles for adenosine receptors on myeloid cells
Bone marrow derived macrophages exposed to Th2 cytokine treatment
followed by hypoxia exposure and co-treatment with either pan-adenosine receptor
agonist and ADORA2A or ADORA2B antagonism showed reductions in AAM
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expression and profibrotic mediator production. Similar reductions were observed
after hypoxia and Th2 cytokine treatment in mice with ADORA2A and ADORA2B
global deletion as compared to wild-type control mice. Although, reductions in AAM
and IL6 expression were more significant with ADORA2B antagonism or deletion,
reductions secondary to ADORA2A antagonism or deletion are also evident. These
observations are not surprising however given the work by Csoka et al. showing a role
for ADORA2B and to

a lesser extent ADORA2A in mediating differentiation of

macrophages after IL4 and IL13 treatment to the AAM subtype(108). As such, it would
be interesting to evaluate how a mouse lacking both ADORA2A and ADORA2B on
myeloid cells would respond to bleomycin treatment.

Contribution of recruited versus resident macrophages
The robust response of ADORA3 to combined Th2 cytokine and hypoxia
treatment do reveal limitations of the in vitro bone marrow derived macrophage
system. ADORA3 is known to be elevated in bone marrow and peripheral
mononuclear cells and are more representative of the circulating monocytes which
travel through the vasculature and migrate to sites of injury or tissue of interest where
they mature (139{Lech, 2013 #218, 140). Resident macrophages are believed to be
the key players involved in acute inflammation in the lung even differentiating to the
AAM subtype to promote repair in addition to Arginase-1 positive recruited
macrophages(140). This observation elicits the question of what if any differences
exist in adenosine receptor expression between recruited macrophages, such as
those derived from bone marrow monocytes, and resident lung macrophages. Future
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work investigating the contribution of ADORA2B or HIF1A specific deletion in resident
(CD11c+) or recruited (CD11b+) macrophages in a bleomycin-induced model of lung
injury will be useful to distinguish the differences in HIF1A-mediated changes in
adenosine receptor expression, macrophage differentiation, and subsequent effects
on acute or chronic lung disease(141, 142). Flow cytometry can be utilized to identify
lung macrophage as alveolar (CD45+CD68hiF4/80+CD11b-CD11c+Gr1-), interstitial
(CD45+CD68lowF4/80+CD11b+CD11c+Gr1-CD14low),
(CD45+CD68lowF4/80+CD11b+CD11c-Gr1lowCD14hi),

monocytes
or

dendritic

cells

(CD45+CD68hiF4/80-CD11c+Gr1-CD103+major histocompatibility complex (MHC)
class IIhi) (143). Chao et al suggest that it is the alveolar macrophages when activated
by hypoxia that contribute to mast cell degranulation and subsequent inflammation
(144). Additionally, adenosine receptor expression may also differ between BALF
macrophages of patients with and without IPF in comparison to murine lung or BAL
macrophages after bleomycin exposure.

Does HIF1A stabilization in other cell-types in contributing to the development
of lung fibrosis?
Although we demonstrated that HIF1A is stabilized in AAMs in patients with
and without IPF patients along with bleomycin-induced models of lung injury, these
findings should be validated in BALF macrophages from human IPF patients samples
as well. Examination of HIF1A stabilization in bleomycin exposed Hif1::LUC reporter
mice along with work by Weng et al. suggest HIF1A activation in other key cell types,
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such as type 2 alveolar epithelial cells, can contribute to epithelial cell proliferation and
the development and progression of fibrosis(84).

Effect of HIF1A inhibition, systemic versus localized, or myeloid-specific
deletion on the development of pulmonary hypertension
In this dissertation, HIF1A was inhibited systemically through intraperitoneal
delivery of 17-DMAG in late stages of bleomycin-induced lung injury. Evaluation of
HIF1A levels in whole lung lysate showed that systemic 17-DMAG delivery was still
able to achieve significant HIF1A knockdown which was associated with reductions in
ADORA2B, AAM expression, and reduced lung fibrosis. Further experiments however
should utilize targeted delivery to the lung through intranasal or intra-tracheal delivery
of antisense oligonucleotides against HIF1A in order to minimize adverse effects of
systemic 17-DMAG delivery, including fatigue, anorexia, renal dysfunction, and
peripheral neuropathy(145). Localized or targeted delivery is also more desirable for
translating therapies into novel treatments for patients.
Pulmonary hypertension is a known co-morbidity of patients with IPF. We
demonstrated that myeloid-specific ADORA2B deletion followed by bleomycin
exposure will result in improved pulmonary function parameters in comparison to
control mice possessing ADORA2B on myeloid cells. Investigating the impact of
myeloid-specific HIF1A deletion and inhibition of HIF1A in late stages of disease on
the development of pulmonary hypertension will be insightful and could be potentially
used in conjunction with existing therapies to treat PH associated with lung disease
and idiopathic PH.
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Possible contribution of HIF2A in myeloid cells to ADORA2B expression,
macrophage differentiation, and fibrosis development
HIF2A has recently been shown to contribute to the development of pulmonary
hypertension and fibrosis in mouse models as well. Hickey et al. illustrated that
homozygous mutation of VHL, contributes to the development of pulmonary edema,
vascular remodeling, pulmonary hypertension, macrophage infiltration, and fibrosis
which was reduced with the introduction of HIF2A heterozygosity(121). Hypoxiainduced HIF2A stimulation has also been found to drive miR-120 expression in
fibroblasts, repressing the c-myc inhibitor, MNT, driving the proliferation of IPF
fibroblasts(146). Similarly, hypoxia-dependent HIF2A stabilization was recently shown
to increase Arginase-1 expression inhibiting vasodilatory effects of its competing nitric
oxide, leading to the development of pulmonary hypertension(129). To date, HIF2A
expression has been believed to be limited to vascular endothelium and type 2
alveolar epithelial cells(72). Preliminary work with genetic silencing of HIF2A by siRNA
in BMDMs after Th2 cytokine treatment and hypoxia exposure suggest that HIF2A
knockdown can be used as a means to reduce ADORA2B and AAM expression
(Figure 6.2). Given these recent findings, future work will include evaluating the effects
of inhibiting both HIF1A and HIF2A in myeloid cells in addition to myeloid-specific
HIF2A deletion alone after bleomycin exposure on the development of fibrosis.
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Figure 6.2. Genetic silencing of HIF1A and HIF2A alter macrophage
differentiation and ADORA2B expression. Bone marrow derived macrophages
from C57Bl6 mice were treated with 10ng/mL IL-4 and 10ng/mL IL-13 for 72 hours
and then incubated in 2% O2 hypoxia for 12 hours in the presence of control siRNA,
siRNA against HIF1A, and siRNA against HIF2A. (A) Immunoblot for HIF1A, AAM
marker, CD206, ADORA2B, and -actin and (B) Arginase-1 expression, assessed
using real-time PCR. Data presented as %-actin.

Effect of Hypoxia-dependent versus hypoxia-independent pathways on
ADORA2B and the development of pulmonary fibrosis
HIF1A has also been shown to be stabilized in the absence of hypoxia through
metabolites such as succinate, mechanical stretch, NF-kb activation (73-77). There is
also evidence that ADORA2A and ADORA2B can mediate changes in glycolytic flux
in association with the observation that CAMs and AAMs also utilize differing
metabolic pathways(48, 74). Future work will include delineating the impact of
ADORA2B in myeloid cells on macrophage metabolism, HIF1A stabilization, and
macrophage

differentiation.

Understanding

these

pathways

and

changing
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metabolomics of macrophages in the setting of hypoxia-induced and normoxiainduced HIF1A stabilization in a bleomycin-induced model of lung injury can potentially
be used as novel targets to stabilize HIF1A in acute lung injury or to inhibit HIF1A in
chronic lung disease.

Understanding the mechanisms behind which HIF1A stabilization in myeloid
cells reduces acute lung injury
We discussed in Chapter 5 the need to discriminate the mechanism by which
HIF1A deletion on myeloid cells exacerbates acute lung injury. This includes
assessing adenosine levels in BALF and evaluating CD73 or expression of other profibrotic or pro-inflammatory cytokines including TGF expression in whole lung lysate
and lung sections. It is possible that HIF1A deletion contributes to CD73 downregulation, thus reducing the production of adenosine in the extracellular space and
reducing adenosine-ADORA2B mediated protective effects in acute stages of
disease.

Interplay of HIF1A stabilization, endoplasmic reticulum (ER) stress, and
macrophage differentiation, and lung injury
Pereira et al. have demonstrated that combined insults of ER stress through
activation of the unfolded protein response (UPR) and HIF1A stabilization can lead to
significant elevations in hypoxia-response genes, including VEGF expression
contributing to pulmonary angiogenesis and pulmonary hypertension development
(147). Additionally, GRP78 is a chaperone protein which in the setting of ER stress,
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recognizes exposed misfolded proteins and activates the UPR. Continued UPR
activation in the setting of ER stress leads to up-regulation of C/EBP homologous
protein (CHOP). Grp+/- mice showed protection from bleomycin-induced lung fibrosis
in association with fewer lung macrophages that were indeed TUNEL, CHOP, and
cleaved caspase-3 positive. CHOP-/- mice after bleomycin treatment however showed
increase in fibrosis and arginase-1 positive lung macrophages (148).
In support of a role for ER stress in AAMs in IPF, lung sections from patients
with IPF and BLM model of lung fibrosis shows increase in CHOP +CD206+
macrophages and other ER stress markers. CHOP-/- protects against bleomycininduced lung injury in association with reductions in fewer Arginase-1 positive
macrophages and reductions in TGF (149). STAT-mediated macrophage activation
is through suppressor of cytokine signaling (SOCS) proteins of which IL-4 upregulates SOCS1, inhibiting STAT1, while IFN up-regulates SOCS3, inhibiting
STAT3(96). The authors conclude that CHOP deficiency up-regulates SOCS1 and
SOCS3 leading to down-regulation of STAT6/PPAR and subsequent disruption of
AAM programing and infiltration into the lungs after bleomycin exposure, reducing
fibrosis. Oh et al. have also demonstrated a role for ER stress in AAM differentiation
in a mouse model of atherosclerosis (150).
These recent studies suggest ER stress as a mechanism to HIF1A stabilization,
AAM differentiation, and the development of pulmonary fibrosis or hypertension in
mouse models of disease. Future work to evaluate the impact of ER stress on
adenosine signaling and HIF1A-mediated ADORA2B expression, macrophage
differentiation, and pro-fibrotic mediator production will be insightful and potentially
lead to the identification of novel targets for drug development.
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Evaluate role of hyaluronan production by myeloid cells in acute lung injury
We have previously demonstrated that myeloid-specific ADORA2B mediated
deletion in mice followed by bleomycin exposure is associated with reduced
hyaluronan production from macrophages in association with reductions in pulmonary
fibrosis and hypertension (113). ADORA2B antagonism has also been shown to
attenuate pulmonary hypertension in a mouse model of COPD in association with
decreases in hyaluronan and enzymes involved in its synthesis including hyaluronan
synthase 2 (HAS2)(151). Interestingly, high molecular weight (HMW) hyaluronan
production by epithelial cells has been found to have a protective effect in ALI (41).
The role of HIF1A and adenosine signaling in mediating this protective effect on
epithelial cells in addition to characterizing hyaluronan production by myeloid cells in
ALI should be investigated in future work to evaluate adenosine-mediated ECM
production as a target for ALI or IPF.

CONCLUSIONS
We utilize an established mouse model of chronic lung injury, lung samples
from patients with IPF, along with a robust in vitro system of bone marrow derived
macrophages to elucidate the effects and interactions of adenosine signaling,
macrophage differentiation, and hypoxia on pulmonary fibrosis. We have illustrated a
role for ADORA2B in mediating macrophage differentiation into AAMs, promoting the
production of pro-fibrotic cytokines in mouse models of lung injury and in vitro culture.
For the first time, we demonstrate inhibition or genetic silencing of HIF1A can
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attenuate pro-fibrotic mediator production and pulmonary fibrosis in bone marrow
derived macrophages (BMDMs) and in vivo models of bleomycin-induced pulmonary
fibrosis. Finally, we reveal a tissue-protective and anti-inflammatory role for HIF1A in
acute stages of lung injury. Further investigations are needed to validate the
mechanism by which deletion of HIF1A contributes to exacerbated inflammation and
subsequent fibrosis in addition to validation in human IPF tissue and macrophage
samples.
There exists a great need to develop novel therapeutics to halt the development
and progression of IPF. Through this work, we have found a role for HIF1A in
mediating ADORA2B expression on macrophages, contributing to their differentiation
into the reparative AAM subtype, and ultimately, contributing to the secretion of profibrotic mediators leading to the progression of lung fibrosis. Genetic deletion of
ADORA2B on myeloid cells and inhibition of HIF1A late stages of disease has
illustrated significant reductions in the development of fibrosis in bleomycin-induced
models of lung injury suggesting their importance as therapeutic targets for drug
development; additionally, myeloid-specific HIF1A stabilization may be another
approach to reduce inflammation in acute lung injury. Much work remains to validate
findings in human tissue samples before moving to clinical trials in patients to
understand the safety, efficacy, and long-term effects of ADORA2B antagonism or
HIF1A inhibition, and HIF1A stabilization, for treatment of IPF or ALI. Ultimately, these
investigations will lead to a better understanding of the role of adenosine in IPF and
ALI, leading to identification of targets for novel therapeutics that can prevent disease
progression and possibly reverse lung fibrosis and inflammation. Additionally, the
inflammatory cell response and fibrosis observed in IPF shares features of other
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common diseases including asthma and systemic scleroderma which respectively
affect up to 300 million and 2.5 million individuals worldwide(152-154). Treatments
developed for IPF may overlap and offer potential benefit in these diseases as well.
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